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Abstract 
Apart from altering normal cellular function, cytopathic viruses cause cell lysis 
and injury while non-cytopathic viruses may lead to latent infections and subsequent 
complications. While both innate and adaptive immune responses are activated by 
infection, the population of virus-specific cytotoxic T-lymphocytes (CTL) is composed 
mostly of CD8 T cells.  During a viral infection, naïve CD8 T cells undergo massive 
proliferation and differentiation. Several studies suggest that most of the activated 
proliferating cells are virus-specific, although there may be a role for activation of 
bystander CD8 T cells and cross-reactive CD8 T cells. Activated CD8 T cells undergo 
differentiation towards distinct functional pathways. Usually after elimination or 
sequestration of the pathogen, the majority of the activated cells will undergo apoptosis. 
The surviving fraction, estimated to be 5-20%, become antigen-specific memory T cells. 
Expansion of memory T cells into secondary effectors results in a more specific and 
faster recall, which is key during re-infection or control of persistent infections. In addition 
to CD8 T cells, other cells of the immune system, costimulatory signals and cytokines, 
play important roles in activating the immune system. Unfortunately, the activities of the 
immune system may injure tissue and result in immunopathological disease. 
Infectious mononucleosis is one such example in which an exaggerated immune 
response to primary Epstein-Barr virus (EBV) infection is thought to cause disease. Little 
is known as to why EBV exposure commonly causes acute infectious mononucleosis 
(IM) in adults, but rarely in children, or why some adults (about 30%) asymptomatically 
seroconvert. One school of thought attributes disease to viral cytopathy while another 
suggests that development of disease is determined by the immune response to virus 
(i.e. CD8 lymphocytosis). The latter model suggests that lymphocytosis is a result of 
activated cross-reactive memory cells, which may increase in frequency with age. 
However, there is no evidence that pre-existing memory T cells become activated during 
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primary EBV infection. One limitation is that most of our understanding of acute EBV 
infection has relied on clinical studies of patients undergoing symptomatic disease. 
Using primary EBV infections in humans as a model, we showed that a 
prospective study allows for capture of a broad range of symptomatic and asymptomatic 
individuals. Lymphocyte expansion was associated with disease severity during primary 
EBV infection and lymphocytosis was also associated with viremia. In reconciling the 
published data, we suggest that viral load in the blood drives NK and CD8 T cell 
expansion.  
Moreover, we used several markers (CD38, HLA-DR, and granzyme B) to 
determine if pre-existing memory CD8 T cells became activated during acute infectious 
mononucleosis. We found that primary EBV infection resulted in bystander activation of 
pre-existing influenza-specific and cytomegalovirus-specific CD8 T cells. However, these 
cells did not generally expand and therefore, the CD8 lymphocytosis observed during 
acute EBV infection was composed largely of EBV-specific cells. Finally, in contrast to 
the mouse model of infectious mononucleosis, in humans, primary EBV infection did not 
result in attrition of bystander influenza and cytomegalovirus memory CD8 T cells.  
These findings outline the significance of studying immunity in humans, because 
our results differed from what mouse studies would have predicted. These finding also 
illustrate the advantages of prospective studies for understanding pathogenesis 
including being able to observe a broader spectrum of disease expression. Finally, these 
results provide unique insight into the underlying immune response of primary EBV 
infection, and suggest potential strategies for controlling EBV-related disease such as 
targeting viral replication to control viral load and suppressing the immune response. 
vii 
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EPSTEIN-BARR VIRUS 
Epstein-Barr virus (EBV) was discovered in 1964 by electron microscopy of suspension 
cultures of African Burkitt lymphoma cells 1.  Four years later, EBV was conclusively linked to 
infectious mononucleosis, which is its most common clinical manifestation 2.  The unifying and 
perplexing characteristic of human herpesviruses including EBV is that acquisition results in 
lifelong infection after the initial viral replication has been contained 3. 
 
THE BIOLOGY OF EBV 
The biology of EBV including virus structure, genome, strain variability, 
replication and latency has been comprehensively reviewed elsewhere 4	  5	  6	  7	  8.  Briefly, 
we focus here on the areas that are crucial for understanding pathogenesis, diagnosis, 
treatment, and prevention of primary EBV infections.  EBV, formally designated as 
human herpesvirus 4 (HHV-4), is one of the eight known human herpesviruses.  Like 
other herpesviruses, EBV virions have a double-stranded, linear DNA genome.  A 
protein tegument lies between the capsid and the envelope, which is embedded with 
glycoproteins that are important for cell tropism, host range, and receptor recognition 9.  
Mature virions are approximately 120-180 nm in diameter 10,11.  The EBV genome of 
approximately 100 genes has been described in detail 8.  
 
Primary Infection and Lytic Replication 
Initial infection is thought to occur in the oral (tonsillar) compartment (see Fig 1).  
The host cells of EBV are mainly lymphocytes and epithelial cells 9.  EBV attaches to B 
cells via binding of the viral gp350 protein to CD21 on B cells 12.  EBV gp42 then 
interacts with B cell human leukocyte antigen (HLA) Class II molecules and triggers 
fusion with the host membrane.  In epithelial cells, which lack CD21, the EBV BMRF-2 
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protein interacts with β1 integrins 13-15, and the EBV gH/gL envelope protein triggers 
fusion via interaction with αVβ6/8 integrins 16.  Endocytosis of the virus into vesicles and 
fusion of the virus with the vesicle membrane releases the nucleocapsid into the 
cytoplasm.  Once the viral nucleocapsid is dissolved, the genome is transported to the 
nucleus where it is replicated by DNA polymerases.  Viral DNA polymerase 
accomplishes linear viral replication, which occurs during the lytic phase of the viral 
lifecycle.  
Tsurumi et al. 7 have published a complete review of lytic and latent replication.  
Briefly, there are three temporal classes of viral lytic gene products (immediate early [IE], 
early [E], and late [L]). BZLF1 and BRLF1 are some of the IE products that further act as 
transactivators of the viral lytic program 7.  Activation of lytic replication or reactivation 
from latency is key to transmission.  The early products (e.g., BNLF2a) have a wide 
array of functions including replication, metabolism, and blockade of antigen processing 
while late products tend to code for structural proteins such as the viral capsid antigens 
and gene products used for immune evasion (e.g., BCRF1).  
An important consequence of EBV infection in B cells is to activate their growth 
program and trigger differentiation into a memory B cell via the germinal center reaction.  
Infected memory B cells are released into the peripheral circulation (see Fig 1), resulting 
in detectable levels of virus in the blood as discussed below.  The number of infected B 
cells decreases over time after the onset of symptoms of primary infection 17, but these 
cells are never entirely eliminated.  
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Figure 1-1: EBV infection in normal carriers. Primary EBV infection begins in the oral 
cavity. EBV uses different glycoproteins to infect epithelial cells and naïve B cells (i.e. 
CD21 on B cell depicted here in yellow). Viral entry results in transport of the EBV 
genome into the B cell nucleus where replication by cellular and viral DNA polymerases 
begins. EBV gene products activate the B cell growth program resulting in the 
proliferation of blasting B cells. Priming of naïve T cells by antigen presenting cells 
occurs in parallel. Normally, these blasting B cells are destroyed by cytotoxic T 
lymphocytes. Once in the circulation, previously activated memory B cells may continue 
to undergo lytic replication or, if EBV shuts down most of its protein encoding genes, 
latency occurs. At a later time, as cells recirculate between the oral and peripheral 
compartments, resting B cells may be activated resulting in viral reactivation and 
shedding. 
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Latency 
Latency is the state of persistent viral infection without active viral production.  
EBV persists mostly in the memory B cell compartment and possibly also in epithelial 
cells 18 (see Fig. 1).  Currently, it is thought that one in a million B cells carry the EBV 
genome in an individual after recovery from acute infection 5.  It is generally thought that 
EBV genomes in latently-infected B cells exist as episomes 19 although it is possible that 
the genomes exist as integrated DNA 11,20.  
In contrast to lytic replication, episomal replication during the latent phase occurs 
via host DNA polymerase.  There is limited expression of EBNA and latent membrane 
protein (LMP) gene products during latency 21.  These include EBNA1, EBNA2, 
EBNA3A, EBNA3B, EBNA3C, EBNA leader protein (EBNA-LP), LMP1, and LMP2.  
Characterization of gene expression patterns in different cell lines (i.e., Burkitt’s tumors, 
EBV immortalized lymphoblastoid cell lines (LCL)) has determined that there are at least 
three different latency programs 18.  By using different transcription programs, EBV latent 
genomes can multiply in dividing memory cells (type I), induce B cell differentiation (type 
II), activate naïve B cells (type III) or completely restrict all gene expression in a context 
specific manner 18,22.  
Only EBNA1 is expressed in the type I latency program, which is seen in Burkitt’s 
lymphoma. CD8 T cells specific for many EBV antigens arise during the immune 
response to natural infection, however not for EBNA1, which contributes to evasion 
during latency 23.  EBNA1 and LMP1/2A are expressed in the type II latency program, 
which is observed in nasopharyngeal carcinoma and Hodgkin’s lymphoma. LMP1 and 
LMP2 are responsible for B cell activation and induction of a growth (proliferation) 
program 5.  The type III latency program, in which all of the latency gene products are 
expressed, is often detected during acute infectious mononucleosis or in certain 
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immunocompromised individuals.  Multiple factors that regulate gene expression in 
latency have been documented 22.  
 
Reactivation 
Latently infected B cells can occasionally be stimulated to reactivate EBV.  This 
produces virus that can reinfect new B cells and epithelial cells, becoming a source of 
viral transmission (see Fig. 1).  Although much is known about the molecular pathways 
involved in viral reactivation 24, what triggers reactivation in vivo is not known precisely.  
The presumption is that it occurs when latently infected B cells respond to unrelated 
infections because B cell receptor stimulation triggers reactivation in B cell lines.  It is 
also not known what fraction of EBV infected cells are in the lytic or latent phase at any 
point in time, although a technique using serum from EBV-infected individuals may prove 
useful in the future 25.  Understanding how each gene product, whether lytic or latent, 
contributes to the pathogenesis of EBV-related diseases should lead to more rational 
and effective prevention and treatment strategies.  
 
EBV EPIDEMIOLOGY 
Young children acquire primary EBV infection most likely from close contact that 
involves exchange of oral secretions via shared items such as toys, bottles, and utensils.  
Before the age of 10, primary infection is usually asymptomatic or produces an acute 
illness that is often not recognized to be due to EBV 26.  In adolescents and young 
adults, however, primary EBV infection frequently presents as infectious mononucleosis, 
a clinical syndrome named by Sprunt and Evans in 1920 and discussed further below 27. 
Hoagland argued convincingly that infectious mononucleosis was acquired “chiefly by 
direct intimate oral contact which allows for salivary exchange” 28.  His hypothesis was 
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strengthened by the lack of transmission among roommates 29-31 and failure to infect 
experimental volunteers 32.  He was also able to estimate its incubation period thanks to 
a patient who described a one-time, intense kissing experience 47 days before the onset 
of infectious mononucleosis.  Hoagland questioned 73 subsequent patients, and 71 
(97%) of them reported oral contact 32 to 49 days before developing infectious 
mononucleosis, which corresponds to an incubation period of approximately 6 weeks.  In 
addition, an incubation period of 38 days has been reported for a well-documented case, 
which is consistent with Hoagland’s observations 33. 
Aside from oral transmission, EBV has been acquired from blood 34, indicating 
that virus present in the peripheral circulation, most likely in memory B cells 17, is or may 
become infectious.  EBV can also be acquired from transplanted hematopoietic cells 35,36 
or solid organs 37 and such infections can be life-threatening especially among recipients 
who were EBV-naïve before transplantation 38.  Several reports of intrauterine 
transmission of EBV have been published but none has been substantiated by 
appropriate viral studies 39,40.  Scottish investigators believe that EBV may be transmitted 
via genital secretions during penetrative sexual intercourse 41,42.  However, their data are 
retrospective and based on only 2 questionnaires completed 3 years apart.  
Furthermore, because kissing and sexual intercourse are virtually inseparable, oral 
transmission certainly cannot be ruled out. 
The seroprevalence of EBV varies widely by geographic location 31,43-45.  Data indicate 
that primary EBV infection occurs at a younger age among persons from lower versus higher 
socioeconomic backgrounds 46,47, which has been attributed to crowded living conditions 26.  
Acquisition of EBV by young children indicates that it can be transmitted without deep kissing.  
However, this does not rule out saliva as the source of EBV because young children commonly 
share objects that they put in their mouths. 
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Healthy people continue to shed EBV for many months after their acute infection 
and are potentially capable of transmitting it 48,49.  Because such virus “donors” are 
asymptomatic and hence not considered to be the source of infection, they often go 
unrecognized.  For the most part, shedding becomes intermittent rather than continuous 
several months after the primary infection.  Hadinoto et al. recently reported that EBV is 
shed continuously in the saliva at relatively stable levels over short periods (hours or 
days) but quantities varied as much as 4 to 5 log10 copies over months or years 17 .  This 
suggests that a person’s likelihood of transmitting EBV fluctuates over time. 
No clear-cut seasonal pattern for infectious mononucleosis has been recognized 
50,51.  However, more cases have been documented among U.S. college and university 
students when school is in session than during semester breaks 50 and Leard observed 
over a 12-year period that there was an October peak in admissions for infectious 
mononucleosis to the Boston University infirmary 52.  A peak incidence during June-
August was reported among patients in the Israeli Defense Force 53, which the authors 
ascribed to more socializing of young people during the summer. 
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PRIMARY EBV INFECTION 
Infectious Mononucleosis 
Infectious mononucleosis was the name chosen by Sprunt and Evans to describe 
a syndrome that resembled an acute infectious disease accompanied by atypical large 
peripheral blood lymphocytes 27.  We now understand that these atypical lymphocytes, 
also called Downey cells, are activated CD8 T lymphocytes, most of which are probably 
responding to EBV-infected B cells.  
Infectious mononucleosis most often begins insidiously with vague malaise 
followed several days later by fever, sore throat, swollen posterior cervical lymph nodes, 
and fatigue.  Some patients experience an abrupt influenza-like onset with fever, chills, 
body aches, and sore throat.  Table 1 displays the relative frequency of signs and 
symptoms compiled by combining data from other investigators 53-57 and our own 
experience 48,58,59.  It should be emphasized that the diagnosis of infectious 
mononucleosis cannot be made on clinical grounds alone. 
Hepatitis, documented by abnormal liver function tests, is seen in 80% of cases 
and thus should be considered part of the acute disease rather than a complication.  
Liver involvement is subclinical in 90-95% of patients but the remainder develop jaundice 
and a few of them complain of tenderness in the right upper quadrant of the abdomen 
that is likely due to hepatic swelling with pressure on the liver capsule.  Eyelid edema, 
which gives the patient a slit-eyed appearance and may be accompanied by facial 
puffiness, is a useful clinical clue if present because it is unique to primary EBV infection 
60. 
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TABLE 1-1. Prevalence of signs, symptoms and laboratory abnormalities in 
infectious mononucleosis 
Finding Prevalence 
(%) 
Comment 
Signs   
   Pharyngitis 100 Occasionally seen without sore throat 
   Cervical lymphadenopathy 95 Especially posterior cervical and 
postauricular 
   Fever 50 Often masked by antipyretics 
   Hepatomegaly 25  
   Splenomegaly 33  
   Eyelid edema 10 Unusual in other acute illnesses 
   Rash 5 Virtually all patients given penicillin 
derivatives develop a rash 
Symptoms   
   Sore throat 95 Many patients describe this as the 
“worst” they have ever had 
   Fatigue 90 Usually the last symptom to resolve 
   Headache 75 Common but underappreciated 
   Feverish 70  
   Body aches 50 Patients describe this as “like the flu” 
   Decreased appetite 50  
   Abdominal discomfort 40 Due to mesenteric adenitis or 
hepatosplenomegaly 
Laboratory Abnormalities   
   ALT elevation  80 5-10% of patients are jaundiced 
   Leukocystosis 40 Usually due to increase in CD8 
cytotoxic lymphocytes 
   Thrombocytopenia 25 Thought to be autoimmune 
   Anemia 10 Thought to be autoimmune 
Median duration of illness 16 days Mean, 19 days 
Based on a compilation of published series 53-57 and 116 subjects followed in natural 
history and treatment trials at the University of Minnesota 48,58,59. 
 
 
Recovery is gradual and it may take months for the patient to feel entirely well 57.  
Fatigue interferes with productivity and quality of life and is usually the last symptom to 
resolve.  Recrudescence of symptoms before the acute illness ends occurs occasionally 
56.  However, recurrences or “second cases” of infectious mononucleosis documented by 
laboratory evidence of active EBV infection after recovery from the acute illness are very 
uncommon.  Hoagland reported no recurrences in his series of 200 patients, most of 
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whom were hospitalized during their acute illness according to military policy 55.  We 
have had just one laboratory-documented recurrence among 116 subjects who acquired 
infectious mononucleosis between the ages of 16 to 26 years (H. H. Balfour, Jr., 
unpublished data). 
The risk of developing infectious mononucleosis after primary EBV infection 
correlates with the age of the patient 51.  Children younger than 10 are usually 
asymptomatic or moderately ill with a partial infectious mononucleosis syndrome, 
although classic infectious mononucleosis can occur in this age group 61.  Primary EBV 
infection among adolescents and young adults may also be asymptomatic but at least 
half of them develop full-blown infectious mononucleosis (H. H. Balfour, Jr., unpublished 
data).  The reason for this age-specific severity of illness remains elusive.  The severity 
of primary EBV infection in adults increases with age and patients older than 40 are 
especially prone to serious illness 62,63.  They have more prolonged fever and more 
serious hepatic involvement but less noticeable lymphadenopathy than younger patients. 
Many complications have been associated with infectious mononucleosis but 
nearly all of them are uncommon or rare 64-66.  Table 2 lists the complications whose 
frequency is estimated to be at least 1%. The following complications, listed 
alphabetically, have been described in fewer than 1% of patients: conjunctivitis, 
hemophagocytic syndrome, myocarditis, neurologic diseases other than 
meningoencephalitis, parotitis, pancreatitis, pneumonitis, pericarditis, psychological 
disorders, and splenic rupture 64-68.  The latter is a rare but greatly feared complication 
that excludes athletes from contact sports for variable periods of time (see the section on 
Limitation of Activities below). 
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TABLE 1-2. Complications reported in ≥1% of cases of infectious mononucleosis 
Complication Comment 
Airway obstruction Due to oropharyngeal swelling and edema 
Meningoencephalitis Other neurologic complications have been reported but are rare 
Hemolytic anemia Thought to be autoimmune 
Thromobocytopenia Thought to be autoimmune 
Rash Rash due to EBV is uncommon, but maculopapular rashes 
occur in the majority of patients inadvertently given penicillin 
derivatives 
 
 
Asymptomatic or Unrecognized Primary EBV Infections 
As stated above, EBV infections in children under the age of 10 are often 
overlooked, either because they are entirely asymptomatic or do not present with a 
typical infectious mononucleosis syndrome.  A clinical dilemma for making the correct 
diagnosis in children is that point-of-care laboratory tests, which are essentially all 
heterophile antibody assays, may be falsely negative 61,69.  Hence, even suspected EBV 
infections in children may not be confirmed.  Primary EBV infection may not be 
recognized in adolescents and young adults either, but 90% of them report some 
symptoms especially sore throat if seen shortly after the onset of infection (H. H. Balfour, 
Jr., unpublished data) and could be diagnosed with appropriate laboratory tests.  
 
DIAGNOSIS OF EBV INFECTION 
Primary EBV infection can be diagnosed with certainty only by utilizing the 
appropriate laboratory tests.  Patients who are mildly ill are unlikely to be identified 
because they either do not seek medical attention or EBV infection is not considered in 
the differential diagnosis.  Patients with a typical infectious mononucleosis syndrome 
(described above) are still a diagnostic challenge because their signs and symptoms are 
not very sensitive or specific for EBV infection.  For example, a recent report found that 
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the classic triad of fever, sore throat, and lymphadenopathy had a sensitivity of 68.2% 
and a specificity of 41.9% for EBV infection 53.  
Several signs and symptoms point to an EBV etiology (Table 1).  These include a 
very sore throat that appears inflamed, swollen, and sometimes has a membranous 
exudate, symmetrical posterior cervical and postauricular lymphadenopathy, and eyelid 
edema often accompanied by facial puffiness.  Clinical findings that militate against EBV 
infection are rhinorrhea, cough, and rash, unless the patient is taking ß-lactam 
antibiotics, in which case the rash is due to transient hypersensitivity to penicillin 
derivatives induced by EBV 70,71. 
 
Nonspecific Laboratory Tests   
Nonspecific laboratory test that hint at infectious mononucleosis include a 
peripheral blood smear, heterophile antibodies and liver function test.  In 1920, Sprunt 
and Evans reported 6 young adults with very similar acute infections who had “a 
mononuclear leucocytosis instead of the more usual increase in the polymorphonuclear 
leucocytes 27.”  They illustrated the features of these mononuclear cells that 
distinguished them from leukemia.  Several years later, Downey and McKinlay published 
a comprehensive description of the atypical lymphocytes seen in the peripheral blood of 
patients with infectious mononucleosis 72.  As mentioned above, these atypical 
lymphocytes, also referred to as Downey cells, are activated CD8 T lymphocytes, most 
of which are thought to be responding to EBV-infected B cells.  While they are invariably 
present in primary EBV infection, they may also be found in infectious mononucleosis-
like illnesses due to other viruses, especially cytomegalovirus 73. 
In 1932, Paul and Bunnell discovered that heterophile antibodies, specifically 
sheep cell agglutinins, were elevated during acute infectious mononucleosis but not in 
many other diseases and thus could be used for diagnosis 74.  They defined heterophile 
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antibodies as “having the capacity to react to certain antigens, which are quite different 
from, and phylogenetically unrelated to the one instrumental in producing the antibody 
response” 74.  Heterophile tests use various mammalian erythrocytes to detect IgM class 
antibodies, which are present during the generalized immune upregulation that 
characterizes acute primary EBV infection.  
Heterophile antibodies detected using bovine erythrocytes were present in 76 
(96%) of 79 adults during the first 10 days of laboratory-confirmed EBV infectious 
mononucleosis (H. H. Balfour, Jr. unpublished data).  Hence, heterophile tests are a 
sensitive diagnostic method for acute infectious mononucleosis.  The laboratory 
diagnosis of infectious mononucleosis is now almost always made by a heterophile 
antibody test 75.  However, they do have drawbacks.  Approximately 40% of children 4 
years of age or younger do not develop heterophile antibodies during primary EBV 
infection 69.  Thus, the heterophile test may be falsely negative in young children.  
Secondly, heterophile antibodies are nonspecific and may be present in non-EBV 
infections, malignancies and autoimmune diseases 76,77.  Finally, heterophile antibodies 
may persist for a year or more and therefore do not always signify an acute EBV 
infection 78.  
On average, 80% of patients with infectious mononucleosis have abnormal liver 
function during the early stages of infection (Table 1).  Elevated liver enzymes, 
especially alanine aminotransferase, strengthen the clinical impression of infectious 
mononucleosis. 
 
EBV-specific Assays 
Indirect immunofluorescence or EIAs are the common platforms for the detection 
of EBV-specific antibodies.  As discussed above and illustrated by Fig. 2, the profile of 
EIA antibodies present distinguishes acute primary, convalescent, and past infection.  
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Acute primary EBV infection is characterized by IgM antibodies to the early antigen VCA 
in the absence of IgG antibodies to the latent antigen EBNA1.  VCA IgG antibodies may 
be present in acute infection, but in lower quantity than VCA IgM antibodies.  During 
convalescence (from the third week to the third month after onset of illness), VCA IgM 
antibodies dwindle while VCA IgG antibodies rise and persist for life.  Between the third 
and sixth month, VCA IgM antibodies disappear whereas EBNA1 IgG antibodies 
become detectable and persist for life.  All 3 antibodies may be present in late primary 
infection or subclinical reactivation, which can be distinguished from each other by 
performing an IgG avidity assay 79.  An evidence-based correlation of serologic patterns 
with stages of EBV infection has recently been published 80.  This analysis included 
heterophile antibody and EA-D IgG antibody in addition to VCA IgM and IgG, and 
EBNA1 IgG. 
In addition, there are specific test that can detect and quantify EBV.  EBV can be 
identified in tissue samples by immunohistochemical approaches.  In situ hybridization to 
detect EBV-encoded RNA transcripts (EBERs) is the gold standard for detecting EBV in 
tissue 81.  PCR is the technique of choice for detecting and quantifying EBV in body 
fluids and can also be used to quantify the virus in tissue samples 82.  While there are 
options in terms of platforms, volumes, probes, and targets, a multicenter comparison of 
different real-time PCR assays suggested that if samples are tested at one center on the 
same platform, real-time PCR is a precise technique for measuring viral load 83.  
However, substantial quantitative differences were found when samples were tested in 
different laboratories.  This is because the gene targets and assay platforms differ widely 
among laboratories and at present there is no universal quantitative standardization. 
The best matrix to use for monitoring EBV infections is debated.  Because most 
assays employ a DNA template and the matrix tested is usually blood, EBV blood viral 
loads are also referred to as EBV DNAemia.  However, some experts recommend 
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plasma 84 but the majority favor whole blood 85,86.  Copy numbers in plasma are usually 
10 to 100-fold lower than in concomitant whole blood samples.  Immunocompetent 
patients with symptomatic EBV infections have viral loads averaging 5,000 copies/mL of 
whole blood during the first 7 to10 days of illness as compared with levels of 5,000 to 
≥50,000 copies/mL of whole blood in transplant recipients; viral loads during latency are 
rarely >1,000 copies/mL of whole blood (H. H. Balfour, Jr., unpublished data).  
Quantitative PCR is also useful for monitoring the effects of anti-EBV therapy and 
in the evaluation of candidate antiviral drugs 58.  As mentioned above, when used to 
evaluate the response to therapy, the goal is to drive the blood viral load below the level 
of detection or at least to <1000 copies/mL.  In addition, quantitative PCR may be useful 
for making the correct viral diagnosis in patients with atypical clinical features or in young 
children who have heterophile-negative infectious mononucleosis 87. 
 
PRIMARY RESPONSE TO EBV INFECTION 
A potent innate and adaptive immune response occurs during primary EBV 
infection.  This response, although it controls infection, does not eliminate it and the virus 
persists for the lifetime of the infected individual.  Thus, a careful balance between the 
virus and the immune system exists.  The section here will summarize what we have 
learned from virological and immunological studies. 
 
Virologic Events 
Infectious virus acquired by exposure to oral secretions or blood establishes a 
foothold in the oral and/or blood compartment in B lymphocytes, epithelial cells, or both 
88,89.  After that, it takes an estimated 5 to 7 weeks for the primary EBV infection to 
manifest itself as infectious mononucleosis.  Computer simulations based on a scenario 
17 
of multiple rounds of viral replication, with amplification at each step, can predict peak 
viral loads consistent with that observed in natural infection 90.  Unfortunately, there are 
few data on immune or virologic events from samples during the incubation period, as 
patients do not seek medical care prior to the onset of symptoms.  Thus, what happens 
during the incubation period remains a major unanswered question about primary EBV 
infection. Our studies discussed in Chapter 2 provide some insight into these events. 
Because the onset of infectious mononucleosis is often insidious, little is known 
about the virus-host interactions until about the fifth day of illness at the earliest 48,58.  
Viral loads in the oral cavity, especially in oral cells, are on average 1-2 log10 EBV 
copies/mL higher than in whole blood.  As shown in Fig. 2, viral clearance from the oral 
compartment is much slower than from the blood.  Viral loads in oral cells and saliva 
remain elevated for many months 17,48,49,58.  In contrast, virus is eliminated from whole 
blood more rapidly 48.  Detectable virus in the blood is eliminated by the seventh week of 
illness in almost every patient, but it did recur 6 months or more after primary EBV 
infection in 8 (10%) of 78 subjects we have been following for several years (H. H. 
Balfour, Jr., unpublished data). 
Viral DNA detected in the blood is thought to come primarily from infected 
memory B cells 18,91.  It was previously held that EBV only maintains latency in B 
lymphocytes, based in part on the fact that infection was eradicated by an EBV negative 
bone marrow transplant 92.  However, viral gene expression patterns differ when the 
virus emerges from epithelial cells versus B cells in a way that suggests passage back 
and forth 93.  Furthermore, patients depleted of B lymphocytes with anti-CD20 antibody, 
rituximab, still shed virus from the throat 94, suggesting that there could be a reservoir of 
EBV latency other than the B cell. 
One gap in our understanding the implications of viral load on the epidemiology 
and pathogenesis of infectious mononucleosis is not knowing what portion of the viral 
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load is complete and potentially infectious, and what portion is either in episomal or 
unencapsidated form.  The latter could certainly be immunogenic but would neither be 
contagious nor cause tissue-invasive disease 19.  
 
 
Figure 1-2: Kinetics of the EBV-specific antibodies and viral load in infectious 
mononucleosis. At presentation, EBV may not be detected in the blood but is usually 
found in large quantities in the oral cavity. Virus is cleared from the blood much more 
rapidly than from the oral compartment. Oral viral shedding can persist for months and 
recurs intermittently for years in most healthy adults. At the onset of illness, most 
patients have IgM antibodies to EBV VCA; these decline between 2 to 6 months after 
infection. VCA IgG antibodies may be detected as early as the first 2 weeks of illness. 
Essentially 100% of patients have detectable VCA IgG antibodies during convalescence 
and these persist for life. EBNA1 IgG antibodies do not develop until 3 to 6 months after 
infection but then persist for life. 
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Immune Response to EBV 
Innate immune response.  The innate immune system is an important first line 
of defense against viral infections.  Viruses elicit a strong type I interferon (IFN) 
response early after infection.  This is presumed to be the case for primary EBV 
infection, although as alluded to above, the kinetics and quality of this response are 
difficult to study in vivo because of the long incubation period.  Nonetheless, EBV 
potently stimulates IFN production from isolated human plasmacytoid dendritic cells in 
vitro 95.  Viral DNA and protein are recognized by pattern recognition receptors (PAMPs), 
such as toll-like receptors (TLR), which can trigger an IFN response, facilitate the 
activation of natural killer cells, and act in multiple ways to prime the adaptive immune 
response.  Our laboratory has recently defined the transcriptional profile of human blood 
during primary EBV, and both type I and type II interferon regulated genes were strongly 
upregulated (K. A. Hogquist, unpublished data).  There is evidence for the involvement 
of multiple TLR in activating the innate response to EBV, including TLR2 96, TLR3 97, 
TLR7, and TLR9 95.  Interestingly, the virus may also have mechanisms of controlling 
TLR signaling 98.  
The inflammatory cytokines TNFα, IL-6, and IL-1ß were increased in tonsillar 
tissue from patients with infectious mononucleosis 99.  Many studies have detected 
inflammatory cytokines in the serum of individuals with infectious mononucleosis as well 
(Table 3).  Prominent amongst these is IFNγ.  IFNγ is produced by activated T cells and 
NK cells.  Not only is IFNγ itself elevated, the catabolic product neopterin, which is 
produced by monocytes that are stimulated with IFNγ, is also elevated (Table 3).  IFNγ is 
thought to be important for control of EBV infection and reactivation, based on studies of 
a related gammaherpesvirus infection in mice 100-102.  However, high levels of IFNγ likely 
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contribute to the symptoms experienced during infectious mononucleosis, as this 
cytokine is known to cause headache, fatigue, and fever 103.  
Interestingly, type I interferon (IFNα) is not consistently detected in the serum of 
infectious mononucleosis patients 104-106.  This may reflect both the fact that IFNα can be 
difficult to detect, and that it is more likely to be produced early in the response to viral 
infection, before the onset of infectious mononucleosis symptoms and presentation in 
the clinic.  The inflammatory cytokines TNFα and IL-6 are also elevated during acute 
infectious mononucleosis.  Finally, serum IL-2 is elevated during infectious 
mononucleosis consistent with the dramatic expansion of CD8 T cells.   
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TABLE 1-3. Alterations in serum cytokine levels during infectious mononucleosis 
Serum 
Cytokines 
Observed 
Status during 
infectious 
mononucleosis 
Possible Impact on Clinical Pathogenesis 
(in terms of known function) Ref 
Interferon-
gamma 
(IFNγ) 
Elevated Type II interferon, produced by NK cells, and 
Th1 and CD8 T cells. Broad 
immunostimulatory effects.  Important for 
control of chronic infection. Likely inhibits viral 
replication and reactivation. 
104,1
06-
110 
Neopterin Elevated  A pteridine compound released from 
macrophages/monocytes stimulated by IFNγ.   
104,1
07,11
0  
Interferon-
alpha (IFNα) 
Not reproducibly 
detected  
Type I interferon, produced by monocytes and 
plasmacytoid DC.  Broad anti-viral and 
immunostimulatory effects. Important for 
control of acute infection. 
104-
106,1
09  
Interleukin-6  
(IL-6) 
Elevated Inflammatory cytokine produced by T cells 
and macrophages.  Mediator of fever and 
acute phase response.  Promotes B cell 
maturation. 
104,1
09-
111  
Tumor 
Necrosis 
Factor alpha 
(TNFα) 
Elevated 
 
Inflammatory cytokine produced mainly by 
macrophages.  Activates macrophages, 
stimulates acute phase response, and can 
cause liver dysfunction, fever. 
107,1
11 
Interleukin-
12 (IL-12) 
Elevated Cytokine produced by dendritic cells.  
Promotes differentiation of Th1 CD4 and CD8 
T cells.  Enhances NK and CTL cytotoxicity.  
106,1
08  
Interleukin 2  
(IL-2) 
Occasionally 
elevated  
Produced by activated T cells.  Growth factor 
for regulatory T cells. 
106-
109,1
11  
Interleukin-
10 (IL-10) 
Elevated  Immunosuppressive cytokine produced by 
monocytes and T cells.  In combination with 
viral IL-10, may suppress T cell production of 
other cytokines (IFNγ, TNFα) and enable 
systemic spread of virus. 
111-
113 
Transformin
g Growth 
Factor beta 
(TGFβ) 
Elevated  Immunosuppressive cytokine with pleiotropic 
effects.  
113 
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The immunosuppressive cytokines, IL-10 and TGFß, are also detected in the 
serum of infectious mononucleosis patients (Table 3).  Interestingly, the EBV late gene 
BCRF1 acts as an interleukin-10 (IL-10) homologue and shares 84% of its amino acid 
sequence with human IL-10 114.  During acute infectious mononucleosis, both viral and 
host IL-10 are detected in sera 112.  Host IL-10 is produced by monocytes and 
lymphocytes, and functions to suppress T cell proliferation and cytokine production, and 
can inhibit IFNγ production from T cells 115.  Thus it might be predicted that IL-10 
counters the pathogenic effects of IFNγ during infectious mononucleosis.  Consistent 
with this, the highest levels of IL-10 were observed in patients with a shorter duration of 
symptoms 113.  Furthermore, high levels of IL-10 are observed in PTLD patients, and are 
reduced as PTLD resolves with an effective antiviral response (reviewed in 116).  Thus 
overall, it would appear that IL-10 and IFNγ play key roles in the balance of immune 
protection and symptoms during infectious mononucleosis.  
NK cells are another important component of the immune response and are 
thought to play a key role in regulating chronic viral infections 117.  In fact, human NK cell 
deficiencies are associated with increased susceptibility to several viral (and bacterial) 
infections including EBV 118.  NK cell numbers increase during infectious mononucleosis 
106,119,120.  Interestingly, their numbers were inversely associated with disease severity 
106, suggesting that NK cells could play a role in limiting viral replication.  
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Adaptive immune response.  The adaptive immune response to EBV has been 
extensively studied, and was discussed in detail in a recent review 121.  Both humoral 
and cellular immune responses are generated.  The humoral or antibody response is 
critical in diagnosing infectious mononucleosis, and the cellular response (particularly 
the CD8 T cell response) is critical for controlling viral replication, but may also 
contribute to the severe symptoms of infectious mononucleosis. 
The kinetics of specific antibody responses to primary EBV infection as 
measured by enzyme immunoassay (EIA) are shown in Fig. 2.  The first humoral 
response detected is an IgM class antibody directed against the viral capsid antigen 
(anti-VCA IgM).  This antibody was present all 70 of our subjects with primary EBV 
infection who were tested.  Sixty-three (90%) of them were positive within 7 days after 
the onset of symptoms, six became positive during the second week of illness, and one 
did not become positive until 49 days after the onset of illness (H. H. Balfour, Jr., 
unpublished data).  All patients develop anti-VCA IgG antibodies, which peak during the 
first 2-4 months and then persist for life. IgG antibodies to the latent antigen, EBNA1, do 
not develop in most individuals for about 3 months but once they appear, they persist for 
life 122.  Antibodies to the early antigen diffuse (EA-D) are also elicited during acute 
infection in 60-80% of patients, but they are not diagnostic of a specific phase of EBV 
infection and hence are not generally useful 123.  
Anti-gp350 antibodies may be detected after natural exposure to EBV or in 
response to gp350 subunit vaccines (discussed below) 124-127.  Furthermore, it has been 
suggested by Turk et al. that gp350 antibodies enhance epithelial cell infection 128.  
Interestingly, this could suggest another form of immune evasion, this time from 
neutralizing antibodies of the humoral arm, that allows EBV to be maintained in a 
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alternate reservoir (tonsillar epithelium) when its initial reservoir (B cells) are being 
depleted by an active immune response (T cells).  
Both CD4 and CD8 T cells make a robust response to EBV antigens, and over 
50 HLA Class I and Class II epitopes from this virus have been identified 121.  Early in 
infection, CD8 T cells specific for lytic antigens tend to dominate the response, while 
CD4 and CD8 T cells specific for latent antigens do not show such a large burst, but 
persist for life 129.  The massive lymphocytosis in the blood that characterizes infectious 
mononucleosis is thought to consist largely of CD8 T cells specific for EBV lytic antigens 
121, although possible activation of bystander (non-EBV specific T cells) has not been 
rigorously ruled out.  We address this in Chapter 3. 
Interestingly, this large adaptive immune response is thought to be responsible 
for the major symptoms of infectious mononucleosis, as disease severity correlated 
more closely with lymphocytosis than viral load in a small study 130.  Additionally, EBV-
specific CD8 T cells were found to be under-represented in tonsil compared with blood 
early during infection.  This resolved later, suggesting that efficient control of EBV 
infection requires tonsillar homing of CD8 T cells131.  Ultimately, CD8 T cells are critical 
for control of EBV, as evidenced by the occurrence of EBV lymphoproliferation and 
lymphomagenesis in immunosuppressed patients 132 and the efficacy of EBV specific 
CD8 T cell transfers in controlling PTLD 133.   
 
Pathogenesis of Infectious Mononucleosis 
As mentioned above, the robust adaptive immune response is thought to be 
responsible for the major symptoms of infectious mononucleosis.  But the question 
remains, why is the infectious mononucleosis syndrome during primary EBV more 
common in adults than children?  It was proposed that adults through sexual activity 
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acquire a higher viral dose than children through salivary contact 134.  This higher viral 
dose would initiate a larger CD8 T cell response, which would cause the symptoms of 
infectious mononucleosis through production of inflammatory cytokines.  However, at 
least one study found that symptomatic infectious mononucleosis was not associated 
with a higher viral load 130.  Others have speculated that pre-existing immunity to other 
viruses, which cross react with EBV (called “heterologous immunity”) could provide a 
robust CD8 T cell response to primary EBV 135.  This could explain why adolescents and 
adults tend to experience infectious mononucleosis, while children are largely 
asymptomatic, as adults are likely to have broader immune experience in general.  
However, neither the subunit or peptide vaccine studies (discussed below) suggested 
that pre-existing immunity to EBV causes more severe infectious mononucleosis (in fact 
the reverse was observed). Thus, it is unclear how heterologous immunity would impact 
the primary response to EBV.  
Another possibility relates to the innate immune response.  As mentioned above, 
elevated NK cell numbers were shown to correlate with reduced disease severity in 
infectious mononucleosis 106.  It was recently shown in a mouse model of chronic viral 
infection (murine cytomegalovirus) that NK cell mediated lysis of infected dendritic cells 
limited the CD4 and CD8 T cell response and, paradoxically, resulted in viral persistence 
136.  If the large CD8 T cell response is responsible for disease severity during infectious 
mononucleosis, then NK cells may reduce it by limiting the adaptive immune response.  
Thus, in Chapter 2 of this thesis, we asked if NK cell increases are associated with lower 
CD8 T cell responses?  
Finally, high levels of inflammatory cytokines could also be responsible for the 
symptoms observed during acute infectious mononucleosis, produced by either innate or 
adaptive immune cells. Therefore, it is important that future studies examine multiple 
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parameters to better understand the factor(s) that mediate pathogenesis. This thesis 
lays the foundation. 
 
TREATMENT 
Symptomatic Management of Infectious Mononucleosis 
Antipyretics.  Most clinicians favor acetaminophen over aspirin to control fever, 
because of concern that aspirin might increase the risk of hemorrhage into the spleen 
137-139.  Fever usually subsides within a week but has been reported to persist for up to 3 
weeks 55. 
Analgesics.  Pain control is important during the early stages of infectious 
mononucleosis especially for those patients whose throat is so sore that it keeps them 
up at night.  Recommended pain management includes acetaminophen, nonsteroidal 
anti-inflammatory drugs, salt-water gargles, anesthetic throat lozenges, or viscous 
lidocaine hydrochloride 137-139.  Codeine sulfate can be prescribed for subjects who do 
not respond to non-narcotic pain control.  However, codeine can cause constipation, in 
which case stool softeners or laxatives are advisable 137 . 
Fluids and nutrition.  Attention to fluid intake is important especially for febrile 
patients.  Maintaining adequate nutrition is also important but can be challenging 
because many patients are anorexic during the first week or two of illness and food is 
cloying.  
Limitation of activities.  Bed rest is unnecessary but contact sports are 
contraindicated 137-140.  Patients generally adjust daily activities to the level of their 
exercise tolerance.  When may athletes return to contact sports?  There is no 
consensus.  A recent evidence-based review suggested that they may return as early as 
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3 weeks after the onset of illness provided they are afebrile, have no remaining clinical 
symptoms, and have normal energy 140.  
Corticosteroids.  A review of the medical records of Rochester Medical Center, 
Rochester, NY found that nearly 45% of patients with infectious mononucleosis received 
systemic corticosteroids 141.  Hence, the use of corticosteroids in infectious 
mononucleosis is a relatively common practice.  However, an evidence-based literature 
review of 7 studies concluded that there is insufficient evidence to recommend steroids 
for control of the symptoms of infectious mononucleosis 142.  Most authors—and this is 
our practice also—reserve corticosteroids for management of complications, such as 
impending airway obstruction, autoimmune anemia, and autoimmune thrombocytopenia 
137-140. 
 
Antiviral Drugs 
A number of antiviral drugs have in vitro activity against EBV 143-149.  Most of 
these drugs are nucleosides but a few non-nucleosides are also in the pipeline.  
Unfortunately, there is no standard formula for equating in vitro susceptibility with clinical 
efficacy.  For many nucleosides including acyclovir and ganciclovir, plasma 
concentrations do not reflect the active antiviral drug moiety.  Nucleoside analogues 
must first be taken up by virus-infected cells and phosphorylated to their active 
triphosphate derivatives, which then inhibit viral DNA synthesis 150.  Although intracellular 
nucleoside triphosphate concentrations are difficult to measure analytically, the area-
under-curve (AUCs) and half-lives of these active metabolites will most likely have the 
best correlation with in vivo antiviral efficacy.  
Nucleosides are the only class of antiviral drugs that has been evaluated for 
treatment of EBV infections in controlled clinical trials.  These nucleosides are DNA 
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polymerase inhibitors.  They are inactive as given but when anabolyzed intracellularly to 
the active nucleoside triphosphate form, they act as faulty substrates for viral DNA 
polymerase, disrupting or terminating synthesis of the DNA chain (reviewed in151).  The 
monophosphorylation step is accomplished more efficiently by viral-encoded enzymes 
than by host cell nucleoside kinases, thus enhancing the activity of these compounds in 
herpesvirus-infected cells as compared with uninfected cells 150.  The enzyme 
responsible for monophosphorylation in EBV-infected cells appears to be a viral-
encoded protein kinase rather than a thymidine kinase 152,153. 
Acyclovir trials have uniformly shown a reduction of EBV in the oral 
compartment, but clinical efficacy was not demonstrated 154-158.  Subsequently, prodrug 
of acyclovir, valacyclovir, has been studied for clinical efficacy in EBV-related disease.  
Because valacyclovir has an oral bioavailability of at least 50% as compared with 10-
20% for the parent compound 159, it has the potential to exert more potent in vivo anti-
EBV activity.  
Simon et al. 160 performed a 3-arm, placebo-controlled, double-blind trial of 
valacyclovir, valacyclovir with prednisolone, or placebo in children 2-18 years old with 
“EBV illness.”  Although this authors in this study did not substantiate the diagnosis of 
EBV infection, the data did suggest that the overall disease burden was lessened by 
valacyclovir with or without prednisolone as compared with placebo.  In a no placebo 
arm study, Balfour et al. evaluated valacyclovir versus no antiviral drug in 20 University 
of Minnesota undergraduates with infectious mononucleosis due to laboratory-confirmed 
primary EBV infection 161.  In this group, the number of reported symptoms and the 
severity of illness were reduced significantly among the 10 valacyclovir recipients as 
compared with the 10 control subjects.   In summary, the effect of valacyclovir or any 
other candidate anti-EBV drug on blood viral load is worthy of further investigation as 
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reduction in EBV DNAemia could be the antiviral effect most closely associated with 
clinical improvement.  
   
Management of Serious or Life-threatening EBV Disease 
Potentially serious EBV disease in transplant patients is managed initially by a 
reduction of immunosuppression 38.  If that is insufficient to bring the viral infection under 
control, humanized monoclonal anti-CD20 (rituximab) may be administered sometimes 
in conjunction with chemotherapy 162.  In refractory cases, adoptive immunotherapy with 
primed CD8 + T cells 163,164 has sometimes been successful. 
 
PREVENTION 
Minimizing Exposure to EBV  
As discussed above, EBV infections can be serious and even life-threatening in 
transplant recipients.  Primary EBV infection after transplantation could be prevented, at 
least in part, by finding EBV-naïve (seronegative) donors for EBV-naïve recipients.  
However, because >90% of adults worldwide are seropositive, identifying a suitably 
matched seronegative donor is impractical.  Even if an EBV-naïve donor could be found, 
the virus still might be acquired after transplantation by the natural route.  A more 
practical approach would be to immunize transplant candidates several months before 
transplantation, which is discussed in the section on gp350 vaccine below. 
 
Antiviral Prophylaxis 
Antiviral drugs (acyclovir, valacyclovir, ganiciclovir, or valganciclovir) are routinely 
given to patients for 3 to 6 months after transplantation to prevent or suppress 
herpesvirus infections with the major focus being on prevention of cytomegalovirus 
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(CMV) disease.  Some transplant centers increase the antiviral drug to treatment dosage 
in asymptomatic patients with rising CMV DNAemia.  This is called preemptive therapy. 
Whereas anti-herpes drugs clearly reduce the incidence and severity of posttransplant 
CMV disease 165,166, their role in the management of posttransplant EBV disease has not 
been established 167,168.  
 
Vaccines 
Development of a prophylactic vaccine, in our opinion, is the most important 
future step toward controlling the consequences of primary EBV infection.  A 
prophylactic EBV vaccine was proposed by Epstein and Achong in 1973 169 but several 
problems—real or perceived—have hindered its progress 170.  At long last, two very 
different adjuvanted EBV vaccines have been evaluated in placebo-controlled clinical 
trials 127,171.  One vaccine contains a gp350 subunit antigen and the other a CD8+ T-cell 
peptide epitope. 
gp350 subunit vaccine.  The EBV envelope glycoprotein, gp350, (formerly 
known as gp340 or EBV-induced cell membrane antigen) has been considered to be an 
attractive immunogen ever since antibodies to gp350 were shown to neutralize the virus 
172.  Despite a study showing that vaccine-induced anti-gp350 antibodies did not protect 
cottontop tamarins from developing tumors after a lymphomagenic challenge dose of 
EBV 173 work on a gp350 vaccine continued.  
Gu et al. performed a Phase I vaccine trial in Beijing, China using vaccinia virus 
constructs expressing gp350 124.  After the vaccine was shown to be immunogenic in 
seropositive children, EBV-naïve children were studied.  The subjects were 1 to 3 years 
of age. Nine received the vaccine and 10 subjects served as controls.  During 16 months 
of follow-up, 3 of 9 vaccinees were infected with EBV versus 10/10 in the control group.  
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The authors concluded: “it has been shown for the first time that protection against 
and/or delay of EBV infection by the natural route is possible.” 
Several years later, successful production of a recombinant gp350 construct in 
Chinese hamster ovary cells was reported 174.  An adjuvanted EBV vaccine containing 
this antigen was subsequently employed in four clinical trials 125-127.  The first two 
evaluated safety and immunogenicity only 125.  The third was a placebo-controlled, 
double-blind study that also evaluated efficacy by following subjects for up to 19 months 
postimmunization for evidence of EBV infection 127.  The vaccine did not prevent 
infection: 13 (14%) of 90 vaccine recipients became infected versus 18 (20%) of 91 
placebo subjects.  However, it had a significant effect on clinical disease. Infectious 
mononucleosis developed in 2 (2%) of 90 vaccinees as compared with 9 (10%) of 91 
placebo recipients.  Failure to prevent EBV infection while preventing clinical illness 
might actually turn out to be an advantage for the vaccine, if the observation that latent 
infection by a murine counterpart of EBV (murine γ-herpesvirus 68) protected mice from 
subsequent bacterial infection applies to humans 175.  
Finally, Rees et al. administered multiple doses of this vaccine to 16 pediatric 
renal transplant candidates 126.  The vaccine was well tolerated and all 13 evaluable 
subjects mounted an anti-gp350 antibody response.  However, only four made a 
neutralizing antibody response.  Because there was no control group, vaccine efficacy 
could not be assessed but this small Phase I trial did show that pretransplant 
immunization is feasible. 
CD8+ T-cell peptide epitope vaccine.  Another strategy to control expansion of 
EBV infected B cells and prevent infectious mononucleosis is to generate CD8 T cell 
immunity to EBNAs 176.  The potential role of these viral proteins in B cell transformation 
precludes their use in whole protein based vaccines, thus a peptide vaccine was 
generated and tested.  This trial utilized an EBNA3A peptide epitope (FLRGRAYGL) 
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restricted by HLA B8 177 with tetanus toxoid (TT) formulated in a water-in-oil adjuvant as 
a source of T cell help 171.  EBV seronegative individuals were immunized on a two-
month interval schedule.  Of the fourteen enrolled subjects, four received placebo, two 
were immunized with 50 µg dose of peptide and the remaining 8 individuals were 
immunized with a 5 µg dose.  This strategy was effective at generating a peptide specific 
CD8 response in most individuals as measured by ex vivo peptide specific IFNγ 
production.  While this was a small study, no infectious mononucleosis occurred in 4 
peptide-vaccinated subjects who subsequently acquired EBV infection, whereas it did 
occur in 1 of 2 subjects in the placebo group.  
The general utility of epitope vaccines is limited by the fact that they only target 
specific HLA types.  Nonetheless epitope vaccines might be useful for PTLD patients, 
where the HLA type is typically known.  This trial was a also a “proof-of-principle” study, 
which showed that EBV vaccines that generate CD8 immunity are safe and did not 
exacerbate EBV immune responses after primary infection.   
 
SUMMARY OF PROGRESS AND PROBLEMS 
In this chapter, we have discussed the clinical, virologic, and immunologic 
features of primary EBV infection.  The clinical consequences of primary infection have 
been well described for adults after the onset of infectious mononucleosis.  However, 
little is known about the virologic and immunologic events that occur during the long 
incubation period prior to symptoms in adults or in asymptomatic individuals especially 
children.  Further research is needed to determine means to predict who will be most 
severely affected, and to develop therapeutic strategies to reduce symptoms. 
Secondly, the most severe consequences of EBV occur when the immune 
system fails to control infection and/or viral oncogenesis.  The disease-causing role of 
EBV in XLP and PTLD patients is indisputable.  Current knowledge of these diseases 
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has clearly positioned the field to undertake steps toward treatment, but there are few 
candidate antiviral drugs and much work remains to be done to make such therapies 
effective and practical.  Increasing understanding of how specific EBV gene products 
and expression programs contribute to pathogenesis holds promise for more rational 
treatment strategies in the future. 
Finally, an EBV vaccine could reduce the substantial disease burden due to 
primary EBV infection and possibly prevent or modify its chronic sequelae.  However, 
development of an EBV vaccine has been agonizingly slow.  More resources should be 
devoted to this endeavor, which has the potential to reduce the impact of a very common 
infectious disease and could even reduce incidence of certain human malignancies, 
such as Hodgkin’s disease, endemic Burkitt’s lymphoma, and nasopharyngeal 
carcinoma.  While the latter questions are beyond the scope of this thesis, in the 
subsequent chapters, we sought to better understand symptomatic and asymptomatic 
primary EBV infection in humans.
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THESIS STATEMENT 
The introductory chapter 1 summarized current knowledge about EBV including 
gaps in knowledge.  Furthermore, in 2010, at the conclusion of the 14th Biennial 
Conference of the International Association for Research on Epstein-Barr Virus and 
Associated Diseases, Dr Alan Rickinson gave a brief overview of the conference and 
identified future points of interest: 1) What happens in early primary infection? How is the 
switch to latency established? 2) What factors predispose to mononucleosis? 3) How 
does EBV get into T/NK (natural killer) cells? 4) What is the role of EBV in autoimmune 
disease? 5) Can we define a vaccine to prevent infection?  
This thesis addresses aspects of the first two questions.  First, what happens in 
early primary EBV infection (both symptomatic and asymptomatic)?  Second, what are 
the immunologic (CD8 T cells, NK cells, cytokines) and virologic (viremia and virus in the 
oral cavity) correlates of disease severity; what is the association between CD8 
lymphocytosis and NK cell expansion?  Third, is the lymphocytosis seen during primary 
EBV infection all EBV-specific?  Fourth and finally, is there attrition of pre-existing 
memory CD8 T cells to heterologous viral infections after primary EBV infection? 
Thus, in Chapter 2, we set out to understand if a prospective study could be used 
to determine the immune responses that occur after primary EBV infection in 
asymptomatic adults.  We next sought out to define the correlates of severe clinical 
illness and showed that viremia, CD8 T cell and NK cell expansion all correlated with 
disease severity.  We highlight correlations with IL-6, an anti- and pro- inflammatory 
cytokine that may indicate a role for soluble factors created by the immune system in 
disease pathogenesis.  In Chapter 3, we demonstrate that bystander T cells do become 
activated during primary EBV infection, but in general, do not expand.  Finally, we show 
although the primary EBV response is quite robust in nature, attrition of pre-existing 
influenza or cytomegalovirus CD8 T cells did not occur.  
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CHAPTER 2 
 
Insights from a prospective study of primary EBV 
infection: Viral load in the blood is not an irrelevant correlate 
of symptomatic infection 
 
 
 
 
 
 
 
Figures and tables in this chapter subsequently used for publication in Journal of 
Infectious Diseases, Vol 207, Jan 2013, p. 80-88; Balfour HH Jr, Odumade OA, 
Schmeling DO, Mullan BD, Ed JA, Knight JA, Vezina HE, Thomas W, Hogquist KA. 
Behavioral, virologic, and immunologic factors associated with acquisition and 
severity of primary Epstein-Barr virus infection in university students. 
doi: 10.1093/infdis/jis646. Copyright © Oxford Journals.
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Primary infection with Epstein-Barr virus (EBV), a latent chronic herpes virus, 
may result in asymptomatic seroconversion or can lead to the development of clinical 
disease known as infectious mononucleosis.  While there is a robust T cell response 
composed mainly of CD8+ lymphocytes, it is still unclear if lymphocytosis or virus is the 
primary driver of acute disease.  To be able study both the symptomatic and 
asymptomatic EBV-specific immune response, we performed a longitudinal prospective 
study of EBV naïve individuals undergoing natural infection.  In contrast to previous 
studies, these results indicate that infectious mononucleosis occurs in the majority of 
newly infected adults, with a broad range of severity.  In addition to defining the kinetics 
of oral and peripheral blood viral replication, plasma cytokine responses, natural killer 
(NK), CD8+ T and CD4+ T cell activation and/or cell expansion, we identify potential 
correlates of severe disease.  In contrast to previously published data that negate a role 
for EBV itself, our results indicate that viremia is associated with an expansion of CD8 
and NK lymphocytes and correlates positively with disease severity.  Thus, these data 
suggest an important role for viremia in clinical illness in support of developing antivirals 
for controlling EBV-induced infectious mononucleosis.  
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Introduction 
Epstein-Barr virus (EBV) is a double-stranded DNA gamma-herpesvirus that is 
one of the eight known human herpesviruses 121.  EBV is highly prevalent in the human 
population, and usually transmitted through virus-contaminated saliva. Like other 
herpesviruses, primary EBV infection results in acute infection followed by viral latency 
and lifelong infection 121.  Although there are no animal models of primary EBV infection, 
multiple clinical and retrospective studies have been performed in order to understand 
the human antiviral immune response to a chronic virus 121,178,179.  The complex 
interactions between the immune system and EBV result in a spectrum of disease 
presentations that can range from asymptomatic, to acute disease, to propagation of 
tumors 121,178,179.  
The most common acute disease caused by primary infection with EBV is 
infectious mononucleosis (IM).  Clinically, the predominant signs and symptoms include 
pharyngitis and sore throat, cervical lymphadenopathy, fatigue, headache, and fever 178.  
Unlike many viruses that induce lymphopenia, the predominant attribute of infectious 
mononucleosis is elevated white blood cell counts, made up largely of atypical blasting 
CD8+ T cells.  Currently, there is no treatment except supportive care, and sustained 
symptoms including fatigue result in loss of productivity for students, military personnel 
and adult professionals.  
The incidence of IM in response to primary EBV infection is thought to increase 
with age 121.  In developing countries, where seroprevalence is often almost 100% in the 
first 2 years of life, EBV infection occurs without clinical symptoms.  However, later 
infection around the second decade of life, as occurs in the United States and Europe, 
often leads to development of infectious mononucleosis in approximately 25% of cases 
121.  The reason(s) for this dichotomy is largely unknown although there have been many 
speculations. 
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It has been postulated that IM is an immunopathologic disease, where symptoms 
are caused by the massive CD8 T cell response to the virus, and not the virus per se.  
Indeed, CD8 lymphocytosis, and not viremia (viral load in the blood) was associated with 
development of symptomatic disease in a previous study of primary EBV infection 130.  
Furthermore, treatment of IM patients with antiviral drugs reduced viral load in some 
cases but generally did not alter the disease course 58,154-158,160.  An attractive model has 
been put forth, based on the concept of “heterologous immunity”, in which memory T 
cells specific to other pathogens can cross-react with EBV and contribute to the 
lymphoproliferation that characterizes this disease 135.  In support of this model, T cells 
that cross-react with EBV-BMFL1 and Influenza-M1 were identified by stimulating	  T cells 
specific for either EBV or Influenza-M1 with peptides for the converse virus 135,180.  Based 
on these studies, the Welsh group created a matrix of CD8 T cell cross-reactivity that 
they suggest contributes to development of infectious mononucleosis 135,180.  This model 
proposes that repeated exposure to influenza (or other pathogens) during childhood 
results in the overzealous CD8 T cell response that characterizes IM in adults.  
Consequently, to date, infectious mononucleosis is considered to be an 
immunopathologic disease caused by the CD8 T cell adaptive immune response. 
Here we show the findings of a prospective study of primary EBV infection, which 
we argue is a better study design (versus retrospective studies) for understanding 
infectious mononucleosis and the acute phase of the immune response to chronic virus 
infections in humans.  In comparison to the clinical study model, we found there is a 
broad disease expression spectrum during primary EBV infection.  We measured blood 
and oral viral loads, CD8, CD4, and NK cell numbers, as well as T cell activation 
markers (CD38, HLA-DR, and Granzyme B) to define the range and kinetics observed 
during primary infection in young adults and correlate them to disease severity.  
Surprisingly, the data showed a positive correlation between disease severity and blood 
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viremia, CD8 lymphocytosis, and NK cell expansion.  Thus, the data support a revised 
model in which, viremia may result in cytopathic effects, activation of innate and adaptive 
immunity, and in an inflammatory response that results in development of clinical 
disease. 
	   	   	  
40 
Results 
Comparison of a clinical study versus a prospective analysis of EBV infection in 
young adults 
For the prospective study, incoming college freshman at the University of 
Minnesota were screened for EBV-specific antibodies using a quantitative Enzyme-
Linked ImmunoSorbent Assay (ELISA) assay.  Those who had not been previously 
exposed to EBV were recruited to the study.  Subsequently, enrolled study subjects 
were screened for exposure to EBV on an ongoing basis.  Blood and/or oral throat wash 
samples were taken every 4-8 weeks and then evaluated for EBV genomes by qPCR 
and/or for antibodies to EBV viral antigens.  Infection with cytomegalovirus and herpes-
simplex virus were documented in some individual with either qPCR or via presence or 
absence of IgG antibodies for these viruses.  
In order to characterize disease severity on a numerical scale, we utilized a 
previously published scale,	  48 based on how much physical activity was limited (0-3) and 
the intensity of symptoms/pain (0-3) (Table 2-1).  This resulted in a range from 0 
(completely asymptomatic) to 6 (essentially bedridden) for disease severity.  Symptoms 
were recorded using an online reporting system, as well as noted by nurses in the 
clinical record.  Put together, we were able to determine the duration of illness and 
calculate a clinical score (Table 2-2) based on the top rated signs and symptoms 
attributable to EBV infection	  178.
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Table 2-1: Severity of illness during primary EBV infection was evaluated using a 
previously established 2-prong criterion. Both physical activity limitation and 
symptom/pain intensity are evaluated to create the severity of illness score. Scores 
range from 0 (completely asymptomatic) to 6 (essentially bedridden) 
 
 
Table 2-2. Clinical Score 
Sign or Symptom Weight Given: 
Sore throat  2 
Lymphadenopathy  2 
Fatigue 2 
Headache 1 
Fever 1 
Decreased appetite 1 
Total possible Clinical Score 9 
Table 2-2: A weighted composite of six signs or symptoms was used to calculate 
clinical score during primary EBV infection. Scores range from 0 (asymptomatic) to 
9. 
Table 2-1. Severity of Illness scale* 
Category Point(s) 
Physical activity limitation  
     No limitation  0 
     Attends all classes but fatigues easily  1 
     Misses some classes  2 
     Cannot go to class  3 
Symptom/pain intensity  
     None  0 
     Sometimes bothersome but does not limit activities 1 
     Bothersome all the time when awake and limits some activities  2 
     Severe enough to interfere with sleep and limits most activities  3 
Total possible score 6 
**Reprinted from the Journal of Infectious Diseases. 2005 September 26; 192: 1505-
1512. Balfour et al. “A prospective clinical study of Epstein-Barr virus and host 
interactions during acute infectious mononucleosis”.	  48 
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Of 147 subjects followed in the prospective study for 4-5 years, 66 experienced 
primary EBV infection.  The sample collection time-points for those 66 are shown in Fig. 
2-1 with samples collected during the 42 days prior to symptom onset in 27 subjects, 
which is the putative incubation period of the virus 181.  
 
Figure 2-1.  Prospective analysis allowed sample collection before, during, and 
after primary EBV infection in young adults. Blood samples were obtained from each 
subject at prior to, during and after primary EBV infection (n=67). For each subject, there 
was a minimum of 3 and a maximum of 28 collection timepoints.  
 
 
We compared disease severity in subjects in the prospective study with that of 
subjects who were in the control groups of previous clinical studies referred by the 
University of Minnesota Boynton Health services clinic with a clinical diagnosis of 
primary infectious mononucleosis 58.  We observed lower severity of illness scores 
(prospective median=3, clinical median=5, p<0.001) and shorter disease duration for 
subjects in the prospective study compared to those who sought health services in 
response to primary EBV infection (Fig. 2-2).  In conclusion, clinical studies presented a 
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skewed perspective for understanding acute EBV infection in that they underestimate 
the incidence of IM and are composed of the sickest of subjects.  
 
Figure 2-2: There is a broader range and a shorter duration of disease severity in a 
prospective primary EBV study in contrast to a clinical study. Graphs represent the 
number of individuals with each severity of illness score (left) and the duration of illness  
(right) for each individual (top) in a clinical study and (bottom) in a prospective study. 
(n=10; n=62 respectively). p<0.001 for symptoms duration between the clinical and the 
prospective study. 
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Identifying the kinetics of T cell activation during primary EBV infection 
Multiple studies have previously shown that CD8 T cell numbers in the peripheral 
blood increase dramatically during acute primary EBV infection	  121, often termed “CD8 
lymphocytosis”.  Since lymphocytosis has been previously suggested to be an important 
factor in disease severity 130, we quantified CD8 T cell numbers over time in prospective 
study subjects.  Because cell numbers recovered from blood were variable between 
individuals, we found the data to be more consistent when graphing the ratio of CD8 T 
cells to CD4 T cells in each patient sample.  As shown in Fig 2-3, there was no 
significant difference between using the ratio of CD8 to CD4 T cells and the total number 
of CD8 T cells, reflecting the fact that CD4 T cell numbers did not increase during acute 
IM 182. 
 
Figure 2-3: The ratio of CD8 T cells to CD4 T cells is an appropriate surrogate for 
total CD8 T cell counts. PBMCs from each subject were stained with antibodies against 
CD3, CD4, and CD8. To calculate total cell numbers, the frequency of CD3+ CD8 T cells 
and CD3+ CD4 T cells relative to the live gate was calculated using FlowJo (Treestar) 
and then multiplied by the PBMC count per milliliter of blood. Gated frequency of T cells 
in the CD3+ gate was used to calculate the ratio of CD8 T cells to CD4 T cells. Error 
bars represent standard error of the mean (n=22). 
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Fig. 2-4A shows data from various time points of subject #5036 as an example, 
where the CD8/4 ratio is 0.23 prior to infection, increases to 8.1 during IM, and resolves 
to 0.32 after 40 days.  
 
Figure 2-4: EBV specific T cells expand and contract, however, a majority of total 
CD8 T cells showed a classic expansion/activation pattern during acute infection 
(while a smaller percentage of CD4 T cells are activated). Sample multi-parameter 
flow cytometric analysis of PBMCs from one subject prior to, during and after acute 
infection with EBV. (A) CD4 and CD8 expression on CD3 T cells over time. (B) CD3+ 
CD8 T cells specific for the HLA-A2/YVL epitope identified using peptide-MHCI 
tetramers. (C) Dot plots showing activation markers, CD38 and DR (top) and granzyme 
B (bottom) expression over time on total CD3+ CD8 T cells (black) and A2-YVL 
tetramer+ CD3+ CD8 T cells (red). (D) Dot plots showing activation markers, CD38 and 
DR (top) and granzyme B (bottom) expression over time on total CD3+ CD4 T cells. 
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We used EBV human leukocyte antigen (HLA)-restricted class I tetramers to 
determine the evolution of the EBV-specific CD8 T cell response (Fig. 2-4B).  
Furthermore, we performed phenotypic analysis of both total and EBV specific CD8 and 
CD4 T cells using activation markers HLA-DR (DR) and CD38, and a marker of cytolytic 
activity, granzyme B (GrzmB).  These markers have been used to characterize the 
magnitude and kinetics of effector phenotype T cells for the yellow fever virus (YFV)-17D 
and the smallpox (Dryvax) vaccine studies	  183 and T cell activation in other viral 
infections 184,185.  In this cohort, we observed a significant upregulation CD38 and DR on 
CD8 T cells, and to a lesser extent on CD4 T cells.  This occurred primarily within the 
first 4 weeks of symptom onset (Fig. 2-4C and Fig. 2-5). 
Unlike CD38 and DR, which are expressed at lower levels prior to infection in 
CD8 T cells (average=3.65% + 4.35%), we observed a higher baseline expression of 
GrzmB in CD8 T cells (average=14.48% + 9.83%) (p<0.001).  However, there was a 
significant upregulation of GrzmB on both CD8 T cells (average-64% + 30%) and CD4 T 
cells (average-33% + 32%) during acute disease (p<0.001) and to our surprise, in some 
individuals, CD4 T cells seemed to upregulate GrzmB levels to the same degree as CD8 
T cells (Fig. 2-4D and Fig 2-5).  Finally, downregulation of GrzmB on CD8 T cells 
occurred at a slower rate relative to that of DR and CD38 co-expression (Fig. 2-5).  That 
the kinetics of phenotypic changes as CD8 T cells transition from the effector phase to 
the memory phase varied for individual markers is not surprising 183, however, it was 
interesting that CD4 T cell downregulation of GrzmB occurred at a similar rate as the 
reduction of CD38/DR on CD4 and CD8 T cells. 
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Figure 2-5: In contrast to CD4 expression of GrzmB or CD38/DR, CD8 T cells 
express elevated GrzmB levels, but not CD38/DR after acute primary EBV 
infection. PBMCs from each subject prior to, during and after acute infection with EBV 
were stained with antibodies to CD3, CD4, CD8, HLA-DR, CD38 and granzyme B. (Top) 
Granzyme B expression (left) and activation markers, CD38 and DR co-expression 
(right) over time on total CD3+ CD8 T cells in all subjects. (Bottom) Granzyme B 
expression (left) and activation markers, CD38 and DR co-expression (right) over time 
on total CD3+ CD4 T cells in all subjects. (n=40-58)  
 
 
Identifying the kinetic window for lymphocytosis, and viral load in both the oral 
cavity and peripheral blood during primary EBV infection 
Overproliferaton of CD8 T cells causing an immunopathologic response versus 
viral load in the blood, resulting in viral cytopathy have been suggested by previous 
studies as the potential basis of infectious mononucleosis.  Therefore, we investigated 
the correlations between lymphocytosis, viremia and disease severity.  To do this, we 
first defined the most appropriate kinetic window in which to evaluate lymphocytosis and 
viremia during acute primary EBV infection (Fig. 2-6).  The CD8 T cell to CD4 T cell ratio 
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(CD8/4) of the entire cohort, which was ~0.5 prior to infection, rose to an average of 3-
fold in the first 30 days after symptom onset.  
	   
 
 
Figure 2-6: Lymphocytosis (CD8 T cell and NK cell) and viremia occur over a 
limited time frame during acute infection. (Top) PBMCs from each subject prior to, 
during and after acute infection with EBV were stained with antibodies to CD3, CD4, 
CD8, and CD56. (top left) CD8/CD4 ratio and (top right) CD56/CD4 ratio over time on 
total CD3+ T cells and CD3- cells respectively, in all subjects. (Bottom left) EBV blood 
viral load copies/ml quantitated by PCR in all subjects. Time window depicted here is 
from 50 days prior up until 100 days after onset of symptoms. Red boxes highlight peak 
of parameter indicated. (n=40-58)  
 
 
Although many studies have determined the incubation phase of EBV to be ~40 
days 181, we rarely detected viremia or virus in oral fluids prior to the onset of symptoms 
(Fig. 2-7).  For most individuals, EBV was no longer detectable after 200 days in the 
blood; however, we observed sustained virus in the oral cavity on a continuous basis.  
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Moreover, since oral EBV shedding in the same individual can vary by 4 or 5 logs 17, not 
everyone had detectable oral virus during each collection time point.  
 
 
Figure 2-7: The longitudinal prospective study shows limited viral shedding into 
the blood and limited changes in CD8 lymphocytosis and NK cells expansion after 
acute primary EBV infection is resolved. (Left) PBMCs from each subject prior to, 
during and after acute infection with EBV were stained with antibodies to CD3, CD4, 
CD8, and CD56. (top) CD8/CD4 ratio and (bottom) CD56/CD4 ratio over time on total 
CD3+ T cells and CD3- cells respectively, in all subjects. (Right) EBV viral load copies 
quantitated by PCR (top) per ml of blood and (bottom) per ml of oral cell pellet in all 
subjects. Time window depicted here is from 150 days prior up until 1500 days after 
onset of symptoms. (n=40-58) 
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per group), individuals who experienced a higher NK cell elevation from their post-IM 
baseline (80 days) had more severe sore throats 106.  In this study, NK cell elevation is 
expressed as the ratio of NK cells to CD4 T cells (NK/CD4), a value that reflects the total 
numbers of NK cells since the number of CD4 T cells does not change during primary 
EBV infection (Fig. 2-3).  While the activation of NK cells, as determined by GrzmB, was 
not significantly different before and during acute primary EBV infection (data not 
shown), we observed an expansion of NK cells during acute disease (Fig. 2-6 and Fig. 
2-7).  Furthermore, we identified a window of NK cell expansion (within 30 days after 
symptom onset) that was identical to that observed for CD8 lymphocytosis (Fig. 2-6). 
 
Viral load in the blood is not an irrelevant factor for disease severity during IM 
Since lymphocytosis is characteristic of infectious mononucleosis, we first 
determined if it correlated with severity of illness (SOI) during the first 15 days after 
symptom onset.  We observed a strong positive association between severity of illness 
and the CD8/4 T cell ratio (Spearman r =0.59), CD8 T cell CD38/DR expression 
(Spearman r =0.73) and CD8 T cell GrzmB expression (Spearman r =0.37) (Fig. 2-8).  
Next, since we had previously determined that CD4 T cells also upregulated CD38/DR 
and GrzmB during acute primary EBV infection and since it has been suggested that 
CD4 T cells specific for lytic antigens may help control virus replication 121, we tested for 
correlations between SOI with the frequency of CD4 T cells expressing GrzmB or co-
expressing CD38/DR.  Interestingly, while CD4 CD38/DR positive cells correlated 
positively with SOI (data not shown, Spearman r =0.67), CD4 GrzmB expression did not 
(Fig. 2-8).  Therefore, consistent with previously published data, we found a strong 
positive correlation between CD8 lymphocytosis and disease severity.  
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Figure 2-8: There is a strong correlation between disease severity and CD8 
lymphocytosis and CD8 activation. PBMCs from each subject prior to, during and 
after acute infection with EBV were stained with antibodies to CD3, CD4, CD8, HLA-DR, 
CD38 and granzyme B. Graph shows the correlation between CD8/CD4 ratio (top left, 
n=34), CD38/DR+ CD8 expression (top right, n=20), GrzmB+ CD4 expression (bottom 
left, n=34), GrzmB+ CD8 expression (bottom right, n=34) and severity of illness (SOI). 
 
 
Subsequently, we wanted to determine if viral load would be associated with 
disease severity. Contrary to a smaller clinical study	  130, we observed a positive 
correlation (Spearman r =0.41) between viremia and severity of illness (Fig. 2-9A).  
Although EBV is transmitted through the oral cavity, we did not observe a positive (or 
negative) correlation between oral viral load and SOI (Fig. 2-9A).  If most or all of the 
CD8 T cell expansion and activation is EBV-specific, as has been suggested by others 
121 186, it is possible that CD8 lymphocytosis is driven by the high viral load.  In 
agreement with this, we detected a strong positive correlation (Spearman r =0.47) 
between blood (but not oral) viral load and CD8 lymphocytosis (Fig. 2-9A).  Similar 
correlations were observed between clinical score, which is based on signs and 
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symptoms, and lymphocytosis (Spearman r =0.63), viremia (Spearman r =0.35) but 
again not with oral viral load (Fig. 2-10). 
Finally, consistent with a previous study suggesting NK cell expansion was 
associated with more severe disease, NK/CD4 ratio correlated positively with SOI 
(Spearman r =0.42) (Fig. 2-9B).  Furthermore, the NK/CD4 ratio also correlated 
positively with blood (Spearman r =0.45) but not oral viral load (data not shown).  For 
each individual, the maximum NK cell expansion occurred in those with the maximum 
CD8 T cell expansion (Fig. 2-9B) suggesting that the same singular mechanism is 
responsible for driving expansion of both populations to create the immunopathologic 
response characteristic of infectious mononucleosis.  
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Figure 2-9.  The strong correlations between SOI and viremia and NK expansion 
suggest that viremia is a primary driver of IM. (A) EBV viral load copies quantitated 
by PCR (top) per ml of blood and (bottom) per ml of oral cell pellet in all subjects. Left 
graphs show the correlation between blood viral load (top left) or oral viral load (bottom 
left) and severity of illness (SOI). Right graphs show the correlation between blood viral 
load (top right) or oral viral load (bottom right) and CD8 lymphocytosis. (B) PBMCs from 
each subject prior to, during and after acute infection with EBV were stained with 
antibodies to CD3, CD4, CD8, and CD56. Graphs show the correlation between NK cell 
expansion and severity of illness (SOI) (left) or CD8 lymphocytosis (right). (n=34) * 
p<0.05, **p<0.02, ***p<0.0001. 
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Figure 2-10: Lymphocytosis is associated with disease severity, clinical score, 
and duration of illness while viremia strongly correlates with disease severity and 
clinical score. (Left) Graphs show the correlation between CD8 lymphocytosis and 
clinical score (top) or duration of illness (bottom). (Middle) Graphs show the correlation 
between viral load copies per ml of blood and clinical score (top) or duration of illness 
(bottom). (Right) Graphs show the correlation between viral load copies per ml of cell 
pellet and clinical score (top) or duration of illness (bottom). (n=34) *p<0.05, **p<0.02, 
***p<0.0001. 
 
 
IL-6, and not IFN-γ , correlates with disease severity 
In addition to having cytotoxic potential, EBV-specific T cells make IFNγ during 
acute EBV infection 121.  Indeed, IFNγ can cause symptoms similar to that observed 
during infectious mononucleosis 187,188.  Therefore, we hypothesized that IFN may 
correlate with disease severity.  However since several cytokines are elevated during IM, 
we identified 8 cytokines that might contribute to disease pathogenesis (discussed in 
Chapter 1).  The cytokines studied were composed of antiviral cytokines (type I and II 
interferons (IFNs)), inflammatory/activating cytokines (interleukin-6 (IL-6), IL-12, tumor 
necrosis factor (TNF)-α) and suppressive cytokines (IL-10, transforming growth factor 
(TGF)-β).  
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Figure 2-11: Multiple plasma cytokine levels were found to be elevated during 
primary EBV infection. The levels of 8 cytokines were measured in plasma using a 
luminex-based assay. The graphs here represent in pg/ml of cytokine in a time window 
from 60 days prior up until 60 days after onset of symptoms. (n=42) 
 
 
While several cytokines were elevated during acute infection (Fig. 2-11), cytokine 
levels did not correlate significantly with CD8 lymphocytosis (data not shown).  In 
individuals whose maximum viremia was greater than 3.5 log10 copies/mL, IL-6 levels 
were significantly higher (63% increase, 4.43pg/ml, p=0.008) and so were IL-10 levels 
(42% increase, 7.86pg/ml, p=0.002) versus individuals with viremia less than 3.5 log10 
copies/mL (IL-6 = 2.72pg/ml; IL-10 = 5.52pg/ml).  Furthermore, only interleukin-6 (IL-6) 
significantly varied in terms of severity of illness (Fig. 2-12), and clinical score (p=0.02, 
data not shown).  For those with more severe disease (SOI score of 4-6), there was a 
significant elevation of IL-6 levels during IM (p<0.01).  Interestingly, IFNγ  levels did not 
correlate significantly with viremia, SOI, or clinical score (Fig. 2-12 and data not shown).  
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Figure 2-12.  Plasma levels of the innate cytokine IL-6 show a stronger correlation 
with disease severity than IFNγ . The level of IL-6 and IFNγ were measured in plasma 
using a luminex-based assay. Subjects were divided into two groups based on severity 
of illness: mild or no disease (0-3) and severe disease (4-6). Pre-IM and acute IM values 
were calculated for each group. Unpaired student t-test was used to determine 
significance. 
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Discussion 
Despite the fact that the herpes family of viruses represent more than a quarter 
of chronic viral infections in humans	  179, it is still unclear how to prevent infection and 
establishment of viral latency.  Of relevance, EBV has been the chosen model for 
understanding the immune response to a persistent chronic virus 121. The field’s 
understanding of the immune response to primary EBV infection is derived from studies 
that enroll people who are often currently undergoing seroconversion and has, therefore, 
resulted in several questionable conclusions.  Given the limitations of retrospective 
studies, we performed a prospective analysis of adolescent college students undergoing 
primary EBV infection due to natural exposure.  The findings of this prospective analysis 
have modified the picture of IM to suggest that viral load in the blood is a critical 
determinant, and therefore a valuable target for therapeutics aimed at prevention or 
treatment of EBV-related pathogenesis. 
Contrary to the data published in the field, we observed a greater incidence of IM 
in response to primary EBV infection in adults.  Not surprisingly, IM is less severe than 
clinical studies suggest.  Moreover, instead of a bimodal distribution of clinical 
symptoms, in young adults, infectious mononucleosis occurs in a uniform distribution 
with approximately only 10% of individuals experiencing asymptomatic seroconversion.  
In light of this finding, the notion that IM rarely occurs in children 121 may be a 
misconception due to lack of appropriately designed prospective studies and under-
diagnosis.  The increased duration of illness observed with a clinical study (compared to 
a prospective study) is likely due to the fact that those who seek relief from health care 
services have already had prolonged symptoms.  Therefore, symptoms such as 
extended fatigue and loss of productivity associated with IM in adults may be more 
difficult to diagnose in children due to lack of recognition of prolonged disease.  A 
serologic study of eighty infants (age 3-24 months) indicated that up to 50% are 
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seronegative for EBV 189; however, there is a paucity of epidemiological studies that 
have investigated precise seroconversion rates with individuals in the first decade of life 
and beyond.  In other countries, like China and Africa, EBV exposure occurred earlier 
with approximately 100% seroconversion of children (age <10 years).  However, in 14 
Chinese children with IM 190, a classic triad of fever, lymphadenopathy and tonsillar-
pharyngitis, similar to adult IM 121 was observed.  Since children are generally the 
optimal target age for immunization, it will be of great interest if future studies identify 
whether a similar range or duration of symptoms would be observed in children of 
different geographic locations, age and even socioeconomic status in the United States.  
The findings of this prospective analysis also offer a clear kinetic picture of IM.  
Relative to most viruses, EBV has one of the longest incubation periods of viral infection 
described (~40 days).  Therefore, this methodology allowed us to improve on historic 
studies121 that have only been able to investigate the dynamics of the response from 
onset of symptoms to convalescence and the subsequent healthy carrier phase.  We 
used the number of days post-onset of symptom(s) to normalize the longitudinal time-
course data set.  Surprisingly, increases in CD8 T cells number/frequency and blood 
viral load were generally not observed during the long (presumed) incubation period, but 
rather peaked close to the time of symptom onset (IM).  This suggests that systemic 
infection/response rather than local (tonsillar) infection/response drive symptoms.  
A recent study of the effector CD8 T cell response to smallpox and yellow fever 
vaccines suggest rapid optimal responses may preclude persistence of viruses and 
dictate whether an infection will be acute or chronic 183, although the definition of 
“optimal” may differ based on the pathogen (i.e. activation of naïve cells, suppression of 
effectors).  Furthermore, elevated levels of programmed death-1 (PD-1), a marker often 
associated with T cell dysfunction,191 were detected on total and EBV-specific T cells 
during acute infectious mononucleosis and was positively associated with a higher viral 
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load in B cells 192.  Therefore, during the early phase of infection, CD8 T cells may not be 
functionally equipped to control acute EBV infection.  We find PD-1 induced-suppression 
unlikely because in one study, proliferation of EBV-specific CD8 T cells in response to 
peptide with and without blockade of the PD-1/PD-L1 interaction was minimal 192.  
However, there are many other inhibitory receptors, such as CD244 (2B4) which co-
regulate T cell exhaustion191 and are also upregulated during acute infectious 
mononucleosis 182.  In line with our developing model, it is possible that the longer 
duration of virus in the blood may imply sub-optimal T cell efficacy during acute infection.  
Nonetheless, the data bring to light the potential role of viremia on development of IM.  
Despite an inclusive role for adaptive immunity, the potential contributions of 
innate immune responses in EBV pathogenesis have yet to be clearly defined 193.  A key 
arm for early antiviral responses, natural killer (NK) cells are elevated during acute IM 182 
and in a small study of 6 individuals, NK cell expansion was associated with severe 
primary EBV infection 106.  A more recent study suggests that early viral activation of 
dendritic cells results in production of IL-12, NK cell activation (especially tonsillar NK 
cells) and subsequent limitation of EBV-induced B cell transformation via IFNγ 194.  Even 
though we were unable to investigate the role of tonsillar NK cells, we did detect an 
increase in blood NK cells numbers that was synchronous with the increase in CD8 T 
cell numbers.  While the data does not preclude a model in which failure of tonsillar NK 
cells results in EBV propagation in peripheral blood, it would suggest a common factor 
driving both CD8 T cell and NK cell expansion.  This is in contrast to a model that 
negates the impact of viral load and attributes the development of infectious 
mononucleosis to the CD8 T cell response alone	  130.  
To gain further insight into the pathogenesis of acute infection, we looked at 
correlates of disease severity.  Consistent with the previous study	  130, we observed a 
positive correlation with CD8 T cell lymphocytosis and severity of illness.  Additionally, 
	   	   	  
60 
based on the average duration of illness (14.4 days) and the general time frame within 
which CD8 lymphocytosis occurs (~16 days), the data did not initially refute the 
circumstantial conclusion that IM is an “immunopathogenic” disease (caused by the 
immune response to virus, and not the virus per se)	  121.  Since CD8 T cells produce 
IFNγ, which is elevated in serum of IM patients 104,106-108,110 and IFNγ treatment can result 
in headache, fatigue, rigors, flu-like symptoms, and myalgias 187,188, empirically, it could 
be argued that CD8 T cell production of high levels of IFNγ results in the symptoms 
classically associated with IM.  However, unlike the previous study	  130, we found that 
severity of illness also correlated with blood viral load and not oral virus	  (48 and Fig. 2-9).  
Subsequently, we observed a previously undefined positive correlation between blood 
viral load and CD8 lymphocytosis that could be suggestive of a model where systemic 
viremia drives activation of antiviral CD8 T cells, and therefore plays a critical role in 
disease severity.  While we do not refute the conclusion that IM is an 
“immunopathogenic” disease, we highlight that viral load in the blood, which was 
previously disregarded, is an important aspect of the pathogenesis of IM.  
Further in agreement with this and similar to the previous study looking at NK cell 
numbers and severity of pharyngitis	  106, we found a positive correlation between severity 
of illness and NK cell expansion.  In contrast however, we showed here that NK cell 
expansion correlates positively (and not inversely, 106) with blood viral load.  There are 
several possible explanations for the differences between out studies and those of 
Williams et al.  First, the interpretation of the data presented by Williams et al. is 
confounded by the fact that while NK cell numbers were examined in association with 
disease severity, NK cell frequency (i.e. percentages) were examined when comparing 
viral load in the blood.  Secondly, Williams et al. represented viral load per 106 PBMC 106 
while we represented viral load as the log transformed value of EBV per milliliter of 
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blood.  Because of the massive increase in CD8 frequency during acute IM, using NK 
cell percentages may not accurately reflect the actual changes in the expanding 
immunological compartment.  While this remains a potential source of discrepancies in 
our observation, it is unlikely because in a subset of this cohort, we still observed a 
positive correlation with viral load in the blood and the frequency of NK cells, regardless 
of whether we looked at time of diagnosis or at peak expansion (data not shown).  
More relevant may be the different ways in which peripheral viral load is 
represented.  Our group has shown in the past that plasma and PBMC viral load are 
inferior indicators for host control of EBV infection in comparison to whole blood viral 
load 48.  The data herein is composed of a larger set of individuals with internal controls 
for NK cell numbers and frequency before, during, and after EBV infection.  Therefore. It 
is likely to reflect a more accurate interaction between viral load in the blood, stimulation 
of NK cell expansion, and NK cell antiviral activity.  
The findings of a positive correlation between the blood viral load and host 
response factors such as increased CD8 and NK cell numbers is novel but not 
surprising.  However, it is inconsistent with the previous paradigm 121 that external pre-
existing factors (e.g. memory T cells reactivity to heterologous viruses) control the CD8 
T cell response and result in symptoms during primary EBV infection.  Finally, in support 
of our modified model of EBV pathogenesis, serum cytokine analysis suggested a 
stronger correlation with innate response than adaptive immunity.  Indeed, upregulation 
of granzyme B on CD8 T cells specific for a viral infection is consistent with a type I 
interferon effect 195, however further analysis of type I and II interferon responses may be 
warranted to understand how interferons contribute to both the acute and the latent 
phase of this persistent chronic infection. 
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Therefore, the data suggest that potential strategies for preventing IM could be 
aimed at reducing blood viral load, either directly via antiviral therapy or indirectly 
through vaccination (i.e. to optimize the efficacy of the immune response).  
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Subjects, Materials and Methods 
Design of prospective study  
We recruited healthy volunteers from the University of Minnesota undergraduate 
residence halls in 2006 and 2007 (n=546).  EBV seronegative exposure status was 
confirmed by the lack of IgG antibodies against EBV viral capsid antigen (EBV VCA IgG) 
(n=206).  Of the 206 eligible EBV-naïve subjects, 147 (71%) were enrolled in the 
prospective study.  For enrolled participants, blood was collected at least every 8 weeks 
during the academic year in addition to an electronic monitoring journal to track 
development of symptoms between visits.  Subjects with symptoms consistent with 
acute primary EBV infection were required/encouraged to come in to the clinical virology 
research clinic for both a physical exam and laboratory-confirmation of primary EBV 
infection (n=66).  Healthcare service personnel made the initial diagnosis of infectious 
mononucleosis.  Primary EBV infection was confirmed by the presence of IgM antibodies 
to VCA and/or IgG antibodies to VCA or EBV nuclear antigen1 (EBNA1) and the 
presence of EBV DNA in the blood and/or oral samples as previously published 48 .  
Laboratory diagnosis of primary EBV infection was key to capturing asymptomatic 
seroconversion. Subjects continued pre-scheduled follow-up visits after seroconversion. 
All participants gave informed consent and the University of Minnesota Institutional 
Review Board approved all protocols used. 
 
Sample collection and handling 
Peripheral blood samples obtained from subjects via venipuncture and collected 
in 10ml purple-top EDTA Vacutainer® tubes (Fisher Scientific).  200µl of blood was used 
for DNA extraction and HLA typing.  Peripheral blood mononuclear cells (PBMCs) were 
isolated by Accuspin™ System-Histopaque®-1077 (Sigma-Aldrich) density gradient 
centrifugation per manufacturer’s instructions.  PBMC counts were recorded post-ficoll 
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purification of whole blood during each collection and stored as detailed below.  Once 
pelleted, cells were frozen in 1 x 107 cells/ml aliquots in a cryopreservative solution 
containing 90% FBS and 10% dimethysulfoxide ([DMSO], Sigma-Aldrich).  Samples 
were allowed to slowly freeze at -80°C overnight and then transferred to liquid nitrogen 
for storage until needed.  Cells were rapidly thawed in a 37°C water bath, diluted to 10ml 
in RPNK media supplemented with 50U/ml benzonase (Novagen) (RPNK media: RPMI 
1640 (Cellgro) supplemented with 10% FBS (Atlanta Biologicals), 2% Penicillin - 
Streptomycin (5000U/ml, 5000µg/ml respectively, GIBCO, Invitrogen) and 1% L-
glutamine (29.2mg/ml, GIBCO)).  Cells were then counted using a hemocytometer and 
divided into separate fractions for flow cytometry or RNA processing. 
Participants were asked to gargle 10ml of RPMI media for oral wash samples.  
Oral samples were then split into 2 aliquots: one for EBV quantification in oral 
supernatant and one for EBV quantification in oral cell pellet.  Oral wash cell pellet 
results are adjusted for qPCR volume and then by volume of oral wash used.  DNA was 
extracted from 200µl of either whole blood or oral washings using QIAamp DNA blood 
minikit (Qiagen).  An EBNA1 plasmid standard was used as control and all samples 
were run using ABI TaqMan Universal PCR Master Mix (Applied Biosystem)	  48	  . 
 
Peptide MHC class I tetramers reagents  
Commercial tetramers were acquired from Beckman Coulter: EBV BMLF1259-267 
(GLCTLVAML)-A*0201 ready to use.  Biotinylated MHC-peptide monomers from the 
National Institute of Health (NIH) tetramer facility were obtained for the following: EBV 
BRLF1109-117 (YVLDHLIVV)-A*0201, EBV BRLF1147-155 (RVRAYTYSK)-A*03, EBV 
BZLF1190-197 (RAKFKQLL)-B*08; EBV EBNA3A325-333_ (FLRGRAYGL)-B*08, EBNA3A379-
387  (RPPIFIRRL)-B*07, EBNA3A603-611 (RLRAEAQVK)-A*03. Prior to use, we added PE-, 
or APC-streptavidin (Invitrogen) to the monomers at a 4:1 molar ratio for O/N in the dark 
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at 4°C to generate fluorescent pMHC tetrameric complexes.  All tetramers were stored in 
the dark at 4°C. 
 
Flow cytometry analysis 
PBMCs from each subject were stained with antibodies (e-Bioscience, 
Biolegend, or Invitrogen) against CD3, CD4, CD8, CD56, CD38, HLA-DR and peptide-
MHCI tetramers (NIH tetramer facility or Beckman Coulter), washed, permeabilized, and 
then stained with an antibody to Granzyme B using the BD Cytofix/Cytoperm Kit per 
manufacturer’s instructions (BD Biosciences).  Samples were analyzed on a LSR II 
(Becton Dickinson) and all data was processed using the FlowJo Software from 
Treestar. 
 
Plasma Cytokine Measurements 
For plasma collection, lab personnel centrifuged whole blood for 10 minutes.  
Once separated from the cellular components, a sterile serological pipet was used to 
create 0.5ml to 1ml aliquots.  These were cryopreserved until later use.  Concentrations 
of cytokines in plasma were determined with human multiplex luminex kits (Panomics) 
and read on a BioPlex 200 reader (BioRad).  Samples prior to primary EBV infection 
were used as patients’ baselines.  
 
Statistical Analysis 
All statistical analysis was performed using Prism software (Graphpad) or Excel 
(Microsoft).  Comparisons between groups were performed with either an unpaired two-
tailed t-test with a p value less that 0.05 as the cutoff for statistical significance.  For 
correlations, a Spearman rank correlation coefficient (r) was calculated and linear 
regression line added for clarity. 
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CHAPTER 3 
 
The persistence of CD8 memory T cells for heterologous viral 
infections during primary EBV infection in humans 
 
 
 
 
 
 
 
 
 
This chapter subsequently published in Journal of Experimental Medicine,	  Vol 209, 
Mar 2012, p. 471-480; Odumade OA, Knight JA, Schmeling DO, Masopust D, 
Balfour HH Jr, Hogquist KA. Primary Epstein-Barr virus infection does not erode 
preexisting CD8⁺ T cell memory in humans. doi: 10.1084/jem.20112401. Copyright 
© 2012 Odumade et al. 
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Immunological memory is key to host defense against the multiple different 
pathogens to which humans are constantly exposed.  In the previous chapter, we 
defined the kinetics of the CD8 T cell lymphocytosis that occurs during acute primary 
EBV infection.  However, it was still possible that activation and expansion of bystander 
memory T cells contributed to this lymphocytosis.  Furthermore, acute primary EBV 
infection results in an unusually robust CD8 T cell response in young adults, and thus 
would be predicted to result in attrition of pre-existing memory to other infections.  In 
order to address these issues, we analyzed samples from a longitudinal prospective 
study of primary EBV infection in humans.  
Because CD8 memory T cell attrition could be dependent on the presence or 
absence of cognate antigen, we examined memory CD8 T cells specific for both human 
cytomegalovirus (CMV) and influenza (Flu) antigens, respectively.  Surprisingly, both 
CMV- and Flu-specific CD8 T cells showed signs of activation including upregulation of 
granzyme B, suggesting that primary EBV infection causes activation of bystander CD8 
T cells.  However, Flu- and CMV-specific T cells generally did not expand, suggesting 
that the profound CD8 lymphocytosis associated with acute primary EBV infection is 
composed largely of EBV-specific T cells.  Finally, we did not observe attrition of CMV- 
or Flu-specific T cells, even during acute infection.  In general, the data support the 
concept that a robust CD8 T cell response creates a new memory CD8 T cell niche 
without substantially depleting pre-existing T cell memory for heterologous infections.  
 
 
	   	   	  
68 
Introduction 
Adequate immunological memory is the basis of secondary immunity and 
vaccination.  Unlike naïve CD8 T cells that exist at low precursor frequencies, memory 
CD8 T cells exist at higher frequencies, which allows for faster responses to secondary 
infection.  Therefore maintenance of memory CD8 T cells is an important protective 
aspect of the immune response.  Furthermore, although there is some heterogeneity 
within the memory CD8 T cell populations, there is some overlap in the homeostatic 
requirements (i.e. cytokines) 196.  
Under normal conditions, naïve T cells respond to their cognate antigen by 
undergoing multiple rounds of proliferation and differentiation, which allows for an 
effector response that aids in pathogen clearance.  Classically, after the acute immune 
response, the bulk of the expanded CD8 population undergoes apoptosis and only a 
small fraction is recruited into the memory phase	  197.  It is thought that this acute phase 
attrition is key to making room for future responses to heterologous infections.  
Interestingly, it has been suggested that during sequential heterologous 
infections, pre-existing memory CD8 T cells specific for bacteria	  198, parasites 199 and 
especially viruses 200,201 undergo attrition.  Using lymphocytic choriomeningitis virus 
(LCMV), Selin et al. showed that subsequent heterologous infections with vaccinia virus 
(VV), pichinde virus (PV), murine cytomegalovirus (MCMV) and/or vesicular stomatitis 
virus (VSV) resulted in a reduced frequency	  200, and total numbers 201 of LCMV-specific 
CD8 T cells in the spleen.  Subsequent data looking at human CMV-specific CD8 T cells 
during the onset of acute hepatitis B infection	  202 would suggest that a secondary 
response can outcompete the first.  Put together, proponents of the attrition model would 
suggest that vaccines and robust CD8 T cell responses would result in detrimental gaps 
in the immunological compartment, resulting in the inability to control subsequent re-
infections or viral reactivation. 
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Conversely, recent data published by Veyzs et al. suggest that attrition may not 
occur in the setting of vaccination because with each subsequent immunization in a 
prime-boost model, the number of pre-existing memory CD8 T cells was maintained	  203.  
Nonetheless, in the context of human immunology, where each individual is challenged 
with a broad variety of pathogens and adequate immunity is required for long term 
protection, deciphering the impact of heterologous infections on pre-existing memory T 
cells after an acute infection is essential. 
In order to test this in humans, we chose to study the effect of primary Epstein 
Barr virus (EBV) infection on pre-existing memory CD8 T cells to influenza (Flu) and 
cytomegalovirus (CMV).  As one of the eight known human herpesviruses, primary EBV 
infection results in an acute immune response, characterized by a robust CD8 T cells 
expansion followed by a latent, predominantly immunologically silent chronic infection	  
121.  Transmission occurs via respiratory secretions, saliva, or blood from an EBV-
positive healthy individual to an EBV-naïve person.  When primary infection is 
symptomatic, it causes infectious mononucleosis (IM), which is characterized by a sore 
throat, fever, hepatosplenomegaly, lymphadenopathy, and fatigue.  
Peptide-MHCI tetramers (for Flu and CMV) and/or presence of IgG antibodies 
(for CMV) were used in order to establish prior immunity to Flu and CMV.  We then 
analyzed both the phenotype, the frequency and total number of EBV-, Flu- and CMV- 
specific CD8 T cells before, during, and after acute infection with EBV in a longitudinal 
prospective study.  Interestingly, while pre-existing memory cells became activated 
during acute primary EBV infection, we did not observe a reduction in total Flu- or CMV-
specific CD8 T cells after IM was resolved, suggesting that in an heterologous EBV 
infection in humans, booster immunizations are not necessary to maintain pre-existing 
memory CD8 T cells.  
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In conclusion, we performed the first study of bystander memory CD8 T cell 
activation and attrition in healthy humans upon a natural primary viral infection and 
showed that each memory population studied had a niche independent of the other 
heterologous virus-specific CD8 T cells. 
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Results 
Prevalence of CMV and HSV infection prior to primary EBV infection was low 
We performed a longitudinal study that followed a cohort of 147 Epstein-Barr 
virus (EBV) naïve college students.  67 of these students acquired primary EBV infection 
naturally.  Serum from whole blood was evaluated for EBV genomes by qPCR and for 
antibodies specific to EBV viral antigens.  In order to determine the presence of pre-
existing immunity to herpes simplex virus-1 (HSV-1) and human cytomegalovirus (CMV), 
serums samples were tested for virus specific IgG antibody responses.  HSV-1 
seroprevalence in United States college students is approximately 37.2% in first-year 
and 46.1% in fourth- year students 204, however; of the 67 subjects tested, none were 
seropositive for HSV-1 IgG. CMV seroprevalence on the other hand, was 21.1% (20/95) 
in this cohort, which is also lower than published rates 205.  
 To study existing immunity to an acute virus infection, we studied influenza (Flu).  
We limited the analysis to only individuals who were HLA-A2 positive (51% in the cohort) 
in order to use available peptide:MHCI (pMHCI) tetramers to establish pre-existing Flu 
memory T cells.  In the 17 subjects analyzed (Table 3-1), all but one had CD8 tetramer+ 
T cells for the HLA-A2 Flu matrix 1 
protein (GILGFVFTL).  The outlier 
individual likely reflects a 
mismatch between this reagent’s 
sub-allele and that of the subject.  
Put together, the data suggest a 
high prevalence of Flu-specific 
CD8 T cell memory.  
 
 
Table 3-1. Subject Characteristics 
Variable Subjects (n=24) 
Sex- no (%) 
Male 9 (37.5%) 
 Female 15 (62.5%) 
Average Age- yr 
Mean (Range) 18.7 (18.1 – 20.3) yrs 
Clinic visits per subject - no 
Mean (Range) 15 (6 – 31) 
Prevalence of infections tested 
CMV IgG+ 12/24 (50%) positive 
HSV IgG+ 0/24 (0%) positive 
Flu A2 Tetramer+ 16/17 (94%) positive 
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Total CD8 T cells showed expansion and activation during acute infection 
To define the activation status of CD8 T cells before, during and after primary 
infection, we stained PBMCs with antibodies to granzyme B and to the T cell activation 
markers HLA-DR (DR) and CD38 183,186.  As expected, we observed a marked increase 
in the frequency and number of total CD8 T cells in the blood during acute primary EBV 
infection (Fig. 3-1A and Fig. 3-2).  
 
 
Figure 3-1. EBV-specific T cells showed a classic expansion/activation pattern 
during acute infection.  Sample multi-parameter flow cytometric analysis of PBMCs 
from one subject prior to, during and after acute infection with EBV. (A) Top: CD4 and 
CD8 expression on CD3+ T cells over time. Bottom: CD3+ CD8 T cells specific for the 
HLA-A2/YVL epitope identified using pMHCI tetramers. (B) Dot plots showing activation 
markers, CD38 and HLA-DR (DR), expression over time on total CD3+ CD8 T cells 
(Top) and Tetramer+ CD3+ CD8 T cells specific for HLA-A2/YVL (Bottom). (C) Dot plots 
showing granzyme B expression over time on total CD3+ CD8 T cells (Top) and CD3+ 
CD8 tetramer+ T cells specific for HLA-A2/YVL (Bottom). 
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Figure 3-2: CD8 T cell frequency and numbers are increased during primary EBV 
infection but CD4 T cell numbers are not. PBMCs were stained with antibodies 
against CD3, CD4, and CD8. (A) The graph represents the frequency of CD3+ CD8 T 
cells or CD3+ CD4 T cells prior to (red square), during (black triangle), and after (blue 
inverted triangle) acute primary EBV infection. (B) To calculate total cell numbers, the 
frequency of CD8 or CD4 T cells relative to the live gate was calculated using FlowJo 
(Treestar) and then multiplied by the PBMC count per milliliter of blood. The graph 
represents the total number of CD3+ CD8 T cells or CD3+ CD4 T cells prior to (red 
square), during (black triangle), and after (blue inverted triangle) acute primary EBV 
infection. Wilcoxon signed rank test, p<0.05 considered statistically significant. (n=14) 
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In this subject population, we observed average baseline expression of 3.65% 
+4.35 CD38+/DR+ and 13.7% +8.49% granzyme B+ CD8 T cells prior to EBV infection 
(Fig. 3-1B/C, and Fig. 3-3).  During acute infection, activation resulted in an average of 
65.4% +25.6% CD38+/DR+ and 74.1%+25.6% granzyme B+ CD8 T cells.  In some 
individuals, this level approached 99% (Fig. 3-1, and Fig. 3-3).  CD38, DR and granzyme 
B expression on total CD8 T cells returned to baseline around 150 days past acute 
illness (Fig. 3-1B/C, and Fig. 3-3). 
 
 
 
Figure 3-3: Elevation of CD38/DR and Granzyme B on CD8 T cells. PBMCs were 
stained with antibodies against CD3, CD8, HLA-DR (DR), CD38 and granzyme B. The 
graphs represent the frequency of CD38/DR+ CD8 T cells (top) or granzyme B+ CD8 T 
cells (bottom) over time relative to onset of symptoms (n=24) 
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The robust activation and expansion of total CD8 T cells during acute primary 
EBV infection has been suggested to be largely or entirely composed of EBV-specific T 
cells 121.  To test this, we evaluated CD8 T cells specific to EBV and other viruses using 
pMHCI tetramers (Fig. 3-1A).  EBV-specific T cells expressed high levels of CD38, DR, 
and granzyme B during acute infection, as expected (Fig. 3-1B/C and Fig. 3-4B black 
symbols).  This was observed with both lytic and latent antigens and was consistent 
between individuals with different MHC alleles (data not shown).  The level of expression 
of activation markers on total CD8 T cells returned to baseline more rapidly than on 
EBV-specific T cells (Fig. 3-1B/C).  This discrepancy might reflect different kinetics 
between CD8 T cells specific for different viral epitopes.  Alternatively, it might reflect 
different kinetics between CD8 T cells specific for EBV versus non-EBV epitopes, since 
it has been reported that IFN can cause T cell activation, independent of antigen 
specificity 195,206.  Thus, we considered the possibility that activation of CD8 T cells 
specific for non-EBV antigens also occurred during primary EBV infection.  
 
Activation of pre-existing bystander memory CD8 T cells during acute IM 
We used pMHCI tetramers to detect T cells specific for Influenza (Flu) and 
cytomegalovirus (CMV) to determine the activation status of non-EBV memory CD8 T 
cells.  To ensure we were evaluating pre-existing memory CD8 T cells and not co-
infection, for CMV, we analyzed individuals who were CMV seropositive prior to EBV 
infection.  For Flu, we selected individuals that had a readily detectable population of 
tetramer-positive cells that displayed a “memory” phenotype in samples taken at least 60 
days prior to primary EBV infection.  When we gated on the tetramer+ population prior to 
EBV infection, we observed relatively low levels of activation markers on Flu-specific and 
CMV-specific memory T cells, as expected (Fig. 3-4).  Nonetheless, CMV-specific T cells 
tended to express more granzyme B (and DR) at baseline than Flu-specific T cells (Fig. 
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3-4).  Interestingly, both Flu- and CMV-specific T cells showed upregulation of CD38, 
DR, and granzyme B during acute primary EBV infection (Fig. 3-4).  In some cases, this 
activation occurred at levels nearly equivalent to those of EBV-specific T cells.  By day 
150, the proportion of activated Flu- and CMV-specific CD8 T cells had returned to 
baseline (Fig. 3-4).  Thus, the data clearly demonstrated “bystander activation” of CD8 T 
cells during acute primary EBV infection. 
 
 
 
 
 
 
 
 
 
 
Figure 3-4.  CMV- and Flu-specific CD8 T cells became activated during acute 
primary EBV infection. PBMCs from each subject were stained with antibodies against 
CD3, CD4, CD8, CD38, CD45RA, DR, pMHCI tetramers, and granzyme B. Percent of 
tetramer+ CD3+ CD8 T cells that expressed CD38 (top), DR (middle), and granzyme B 
(bottom) prior to (>40days prior), during (0-30 days), and after (>150days) acute primary 
EBV infection. EBV-specific CD8 T cells were identified with HLA-A2/YVL, or A3/RVR, or 
B8/RAK tetramers; Flu-specific CD8 T cells were identified with HLA-A2/GIL tetramers; 
and CMV-specific CD8 T cells were identified with HLA-A2/NLV, B7/TPR, B8/ELR or 
B35/IPS tetramers. (n=6-19 per virus-specific T cell, p value (ANOVA) *= 
p<0.05**=p<0.001) 
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Flu- and CMV-specific CD8 T cell numbers were unchanged or increased only 
slightly during acute primary EBV infection 
From the data, it appeared that T cells specific for other viruses became 
activated during primary EBV infection.  However, it was unclear if such cells expanded 
and contributed to the CD8 lymphocytosis that characterizes acute primary EBV 
infection	  121, or underwent apoptosis	  201.  To address this, we calculated the total 
numbers of Flu- and CMV- antigen specific CD8 T cells per milliliter of blood before, 
during, and after acute primary EBV infection.  Although we typically observed reduced 
frequency of Flu- or CMV-specific T cells during acute primary EBV (Fig. 3-4A and Fig. 
3-5), the total number of Flu-specific T cells generally remained steady or slightly 
increased (Fig. 3-6).  
 
 
Figure 3-5: There is a transient reduction in the frequency of pre-existing memory 
CD8 T cells during primary EBV infection. PBMCs were stained with antibodies 
against CD3, CD4, CD8 and pMHCI tetramers. The graph represents the frequency of 
Flu (left) and CMV (right) tetramer+ CD3+ CD8 T cells prior to (red squares), during 
(black triangles), and after (blue inverted triangles) acute primary EBV infection. (n=10 
for Flu, n=11 for CMV). Paired student t-test, p<0.05 is considered significant. 
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A modest but transient increase in the number of Flu-specific T cells (Fig. 3-6A) 
was observed in 4 of 15 individuals, and of CMV-specific T cells (Fig. 3-6B) in 2 of 12 
individuals studied.  The other individuals typically showed no increase or decrease of 
Flu-specific (Fig. 3-6C) or CMV-specific (Fig. 3-6D) CD8 T cells during after primary EBV 
infection. 
 
 
Figure 3-6: Flu- and CMV-specific CD8 T cell numbers were unchanged or 
increased only slightly during acute primary EBV infection. To calculate total cell 
numbers, the frequency of CD3+ CD8 tetramer+ cells relative to the live gate was 
calculated using FlowJo (Treestar) and then multiplied by the PBMC count per milliliter 
of blood. The data are sample graphs depicting the total T cells per ml of blood for EBV 
(black diamond), Flu (red circle), or CMV (blue upside-down triangle) over time in which 
non-EBV specific T cells either increased slightly (top panels) or stayed relatively 
unchanged (bottom panels). 
 
 
To determine the relationship between bystander activation and T cell numbers, 
the number of Flu- or CMV-specific T cells per milliliter of blood during acute primary 
EBV infection was normalized relative to the pre-existing virus-specific cell numbers (set 
to 1) for each individual and this value was designated as fold expansion.  When we 
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separated the subjects into two groups based on whether Flu/CMV-specific T cells 
underwent more bystander activation (>30% CD38/DR+) or less (<30% CD38/DR+), we 
found that the cells that underwent a greater extent of bystander activation showed a 
modest but significant increase in total numbers of bystander CD8 T cells in peripheral 
blood (Fig. 3-7).  These data suggest that memory CD8 T cells specific for other acute 
(influenza) or chronic (CMV) viruses undergo bystander activation during primary EBV 
and may contribute to the increase in CD8 T cells numbers in the blood, but only slightly. 
 
 
Figure 3-7: High levels of activation during acute primary EBV infection were 
associated with modest bystander expansion. Graph compares the fold expansion of 
CMV- and Flu-specific CD8 T cells that displayed an activated phenotype (based on 
>30% expression of CD38 and DR) or did not (1-30% expression of CD38 and DR). 
student t-test, p<0.05. (n=26) 
 
 
Finally, we compared both the frequency and the numbers of bulk CD8 and CD4 
T cells and antigen-specific (Flu- and CMV-specific) T cells prior to EBV exposure to 
those after resolution of the acute phase of infection.  As shown in Fig. 3-2, although 
acute primary EBV infection transiently alters the CD8 T cell compartment, both the 
frequency and total numbers of CD8 and CD4 T cells did not significantly differ from 
baseline indicating that homeostasis of the peripheral immune compartment is not 
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compromised by infectious mononucleosis.  Next, we explored whether attrition of pre-
existing memory cells that were activated in a bystander fashion occurred. We compared 
both frequency (Fig. 3-5) and numbers (Fig. 3-8) to account for malleability in the CD8 T 
cell compartment.  Surprisingly, there was no significant loss of either CMV- or Flu- 
specific T cells at later time points after EBV infection (Fig. 3-3, Fig. 3-5 and Fig. 3-8).  
Altogether, these data suggested that there is no attrition of peripheral blood memory 
CD8 T cells during or after heterologous infection in young adult humans. 
 
Figure 3-8: There is no attrition of pre-existing memory CD8 T cells after primary 
EBV infection. Total cell numbers for Flu-and CMV-specific CD8 T cells after 150 days 
post symptom onset were calculated as described above and compared to prior to EBV 
infection. The white bars (Flu) and gray bars (CMV) depict that the total virus specific 
CD8 T cells per ml of blood do not change significantly after infectious mononucleosis. P 
value of paired student t-test, p>0.05 (n= 10 for Flu; n=11 for CMV) 
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Discussion 
Bystander activation during acute primary EBV infection 
Heterologous infections can result in bystander activation of pre-existing memory 
T cells.  In this study, we showed that bystander CD8 T cells undergo activation during 
Epstein Barr viral infection.  Interestingly, we observed activation (increased expression 
of DR, CD38 and GrzmB) for CD8 T cells specific to both influenza (a cleared virus) and 
CMV (a latent virus).  Since the reservoir for CMV includes monocytes, lymphocytes, 
dendritic cells and bone marrow cells 207, it is possible that the activated phenotype of 
CMV-specific T cells might reflect alterations in the viral load of CMV (i.e. viral 
reactivation) during primary EBV infection.  Although we observed no evidence for this, 
the possibility is difficult to rule out due to the many depots for CMV besides peripheral 
blood.  Furthermore, alterations in viral load cannot explain the activated phenotype of 
Flu-specific T cells.  Put together, this suggests that the presence of cognate antigen is 
not necessary for bystander activation of memory T cells during an acute viral infection.  
A few studies in humans have also suggested that bystander T cell activation can 
occur during chronic viral infections.  Doisne et al. 185 showed that EBV-, CMV-, and Flu- 
specific cells exhibited a more activated phenotype (as assessed by DR and CD38) in 
patients with acute HIV infection compared with uninfected controls.  More recently, 
activation of CMV- and EBV- but not Flu- specific cells was observed during acute 
hepatitis B infection 184.  In both studies, the small numbers of patients were not directly 
compared to controls 184 or to samples taken prior to infection	  185.  Nonetheless, it would 
seem that activation of memory T cells specific for heterologous acute or chronic viral 
pathogens is a common occurrence during acute viral infection.  
Both type I IFNs, and IL-15 have been suggested to mediate bystander activation 
in mouse studies 195,206,208.  Both cytokines were also shown to upregulate activation 
markers on human memory CD8 T cells when given at high concentrations in vitro 184,195.  
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Type I IFNs upregulated granzyme B in Flu-specific T cells 195 and IL-15 upregulated DR 
and CD38 on Flu, CMV, and EBV memory T cells 184.  Furthermore, from mouse studies, 
it has been postulated that production of both IFNα and IFNγ can lead to activation of 
STAT1, subsequent production of IL-15 and IL-15Rα, culminating in bystander activation 
of CD122int/hi expressing memory T cells	  209.  Therefore, the contribution of each cytokine 
to bystander T cell activation may not be exclusive.  
Although IFNs have been detected in serum/plasma of infectious mononucleosis 
patients 104-110, IL-15 serum levels were not elevated during acute infectious 
mononucleosis 106.  However, in vitro, EBV induced IL-15 production in cultured 
peripheral blood mononuclear cells (PBMCs) 210.  Notably, this could be because non-
hematopoietic cells might be a relevant source for this cytokine, so it is difficult to make 
conclusions about its potential role in bystander activation during primary EBV infection.  
Since it is difficult to detect certain cytokines ex vivo, one potential approach has 
been to test the impact of each cytokine by looking at gene expression changes.  Both 
acute viral infections 211 and vaccines 212 have been documented to generate a type I 
IFN gene signature.  Preliminary data from microarray analysis of PBMCs suggest that a 
strong type I IFN and type II IFN response occurs during acute primary EBV infection, 
although IL-15 gene expression was not upregulated during acute primary EBV infection 
(Dunmire et al., unpublished data).  Therefore, the gene expression signature during and 
after infectious mononucleosis still needs to be characterized to elucidate the 
mechanism(s) of bystander activation.   
Furthermore, it is necessary to clarify the role that viral load may play in cytokine 
levels.  In HIV infected individuals, activation markers on EBV-, CMV-, and Flu- specific 
T cells were higher than controls, and this was reduced by antiviral therapy 185 implying 
that viral load may induce the cytokines that cause bystander T cell activation.  
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Considering the potential significance of bystander activation (discussed below), if viral 
control is key, developing appropriate antiviral therapies is of utmost importance.  
  
Functional significance of bystander activation 
Despite the potentially common occurrence of bystander T cell activation in acute 
infection in humans (184,195 and this study), it is unclear what the biological significance is.  
For example, the observation of bystander activation of CD8 T cells during primary EBV 
raises the question as to whether the extraordinary CD8 lymphocytosis observed in 
acute infection is composed entirely of EBV-specific T cells as previously suggested	  186, 
or includes bystander T cells.  Addressing this question with pMHCI tetramers has not 
been possible because of the large size of the EBV genome 121, and thus the large 
number of potential antigens that CD8 T cells may respond to.  In this study, we 
observed an increase in the total numbers of CMV- and Flu- specific T cells during acute 
primary EBV infection, however this was only in some individuals, and was modest 
(even in the most highly affected individuals, <2-fold on average).  This was compared to 
the 5-fold increase in total CD8 T cell numbers in the most highly affected individuals.  In 
general, given the high frequency of memory CD8 T cells in adults (~50%), if all of them 
underwent even modest expansion, bystander T cells might comprise between 5-10% of 
the increased peripheral blood CD8 T cells during acute infectious mononucleosis, at 
least in the most affected individuals. 
Moreover, since the precise cause of symptoms during acute primary EBV 
infection remains unknown, it is possible that bystander activation may contribute to 
immunopathogenic or protective aspects of the immune response.  While Doisne et al. 
have suggested that bystander activation is of no consequence to HIV disease 
pathogenesis	  185, it is possible that activation of bystander T cells could contribute to the 
development of clinical symptoms and/or could exacerbate the severity of IM during 
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primary EBV infection.  Indeed, the severity of IM did correlate with the extent of 
CD38/DR or GrzmB upregulation on total CD8 T cells (see Chapter 2, unpublished 
observation).  Based on the suggested mechanisms for upregulation of these activation 
markers 184,195, it would be interesting to see if IL-15 and/or type I IFN induced gene 
changes correlate with disease severity. 
In terms of disease pathogenesis, the limited data correlating immune and viral 
parameters to disease suggest that lymphocytosis is key 121.  Therefore, high levels of 
cytokines produced by both EBV specific and bystander T cells may cause the 
symptoms of acute infectious mononucleosis.  This might explain why adults, who are 
more immunologically experienced than children, experience more severe symptoms in 
response to acute primary EBV infection.  However, we did not observe any difference in 
disease severity between subjects who were CMV infected prior to EBV versus those 
not (CMV-negative= 2.98+1.55; CMV-positive= 2.79+1.48; p= 0.68).  Nonetheless 
humans bear many chronic viral infections by the time they reach adulthood 179, thus the 
contribution of a single one might have little impact. 
 
 
Figure 3-9: CMV pre-infection did not alter disease severity during primary EBV 
infection. The graph represents the severity of illness in individuals who were CMV 
seropositive (circle) or CMV seronegative (diamonds) prior to EBV infection. (n=14 and 
n=46, respectively). p<0.05 considered statistically significant for unpaired student t-test. 
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We document here the bystander activation of pre-existing memory CD8 T cells.  
However, it is possible that naïve, or even tolerized (self-antigen specific) T cells may 
also undergo bystander activation during primary EBV infection.  Furthermore, it remains 
to be determined if bystander memory CD4 T cells become activated to a similar extent 
as CD8 T cells.  Bystander activation of naïve T cells has been observed in animal 
models,213 therefore, further studies will be required to address this potentially important 
issue in humans. 
 
Persistence of pre-existing memory CD8 T cells 
This analysis showed that pre-existing memory CD8 T cells specific for Flu or 
CMV did not wane during the course of primary EBV infection in humans.  This was 
surprising since studies in animal models showed attrition of pre-existing memory CD8 T 
cells during many heterologous infections 198-201,214-218.  Further studies showed that both 
type I IFN and type II IFN can cause memory T cell attrition.  In the bacterial model, 
attrition was dependent on IFNγ	  218, whereas in viral studies, bystander activation was 
dependent on Type I IFN and accompanied by apoptosis 206,213,219  
These findings may be at odds with these other studies for several reasons.  
First, it may indicate that EBV is not a strong IFN inducer, as some of the studies in 
animal models employed poly IC, an extremely potent inducer of type I IFN	  206,213,219.  
However, we find this unlikely because elevations in type II IFN 104,106-110, and less 
consistently type I IFN 104-106,109 have been detected during acute primary EBV infection.  
Furthermore, preliminary microarray data demonstrated a strong type I and type II IFN 
gene signature during acute primary EBV infection (Dunmire et al., unpublished data), 
suggesting that EBV would be a prime candidate for active depletion of pre-existing 
memory T cells.  
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Secondly, there is some evidence that central memory T cells (more likely to 
reside in lymphoid organs) are more sensitive to IFN induced apoptosis than effector 
memory T cells (more likely to circulate in blood)	  220.  In this human study, we measured 
T cell numbers in the blood, in contrast to most animal studies, which focus on 
secondary lymphoid organs.  Therefore, although there are studies that indicate attrition 
is a comprehensive process that occurs in both lymphoid and peripheral tissues	  217,218, it 
is possible that depletion of pre-existing memory cells occurs in the main reservoir of 
viral infection (i.e. lungs, for influenza). 
Finally, this analysis focused on heterologous infection in 18-21 year olds (mean 
18.7) (Table 3-1).  Based on the mouse study of LCMV Clone 13 versus LCMV 
Armstrong suggesting that memory T cell loss is a continuous process in persistent 
infections	  217, the potential impact of EBV, as a latent chronic virus, on pre-existing 
memory may require longitudinal studies over decades.  
On the other hand, these results are consistent with the work of Vezys et al., who 
showed using a prime-boost immunization model, that the CD8 T cell compartment 
expanded without depleting pre-existing memory T cell 203.  However, key to this 
observation was that using a prime-boost model prevented attrition of the LCMV-specific 
memory CD8 T cells	  201.  In agreement with this, attrition of Plasmodium berghei-specific 
CD8 T cells after heterologous infection with LCMV, Listeria monocytogenes, vaccinia 
virus and mouse hepatitis virus 1 was reversed by booster immunizations 199.  
Furthermore, in concert with data demonstrating that attrition is less pronounced in older 
mice than younger mice 219,221, it is possible that attrition will be observed only in the 
context of co-infection or serial heterologous infections.  
In summary, we find that bystander activation of pre-existing memory T cells did 
not result in active depletion during a heterologous infection of EBV in humans.  
Because infection with mouse gammaherpesvirus 68 (MHV-68), the mouse model for 
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EBV infection, has been shown to result in partial depletion of pre-existing Flu-specific T 
cells, 216 these results emphasize the importance of studying immunity in both humans 
and animal models.  Moreover, using a prospective study design, we provide a study 
protocol example that can be used in the future to evaluate current vaccination schemes 
such as measles, mumps, rubella (MMR) that challenge the immune system with 
multiple pathogens at once, and may therefore alter pre-existing immunological memory. 
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Subjects, Materials and Methods 
Design of prospective study  
As described in Chapter 2, we recruited healthy volunteers from the University of 
Minnesota undergraduate residence halls in 2006 and 2007 (n=546).  All participants 
gave informed consent and the University of Minnesota Institutional Review Board 
approved all protocols used.  EBV seronegative exposure status was confirmed by the 
lack of IgG antibodies against EBV viral capsid antigen (EBV VCA IgG) (n=206).  Of the 
206 eligible EBV-naïve subjects, 147 (71%) were enrolled in the prospective study. 
ELISAs were used to determine presence of CMV IgG and HSV IgG antibodies in some 
individuals. 
For enrolled participants, blood was collected at least every 8 weeks during the 
academic year in addition to an electronic monitoring journal to track development of 
symptoms between visits.  Subjects with symptoms consistent with acute primary EBV 
infection were required/encouraged to come in to the clinical virology research clinic for 
both a physical exam and laboratory-confirmation of primary EBV infection (n=66).  
Primary EBV infection was confirmed by the presence of IgM antibodies to VCA and/or 
IgG antibodies to VCA or EBV nuclear antigen1 (EBNA1) and the presence of EBV DNA 
in the blood and/or oral samples as previously published 48.  All participants continued 
pre-scheduled follow-up visits after seroconversion.  
 
Sample collection and handling 
Peripheral blood samples were obtained from subjects via venipuncture and 
collected in 10ml purple-top EDTA Vacutainer® tubes (Fisher Scientific).  200µl of blood 
was used for DNA extraction and HLA typing.  Peripheral blood mononuclear cells 
(PBMCs) were isolated by Accuspin™ System-Histopaque®-1077 (Sigma-Aldrich) 
density gradient centrifugation per manufacturer’s instructions.  PBMC counts were 
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recorded post-ficoll purification of whole blood during each collection and PBMCs were 
stored as detailed below. Once pelleted, cells were frozen in 1 x 107 cells/ml aliquots in a 
cryopreservative solution containing 90% FBS and 10% dimethysulfoxide ([DMSO], 
Sigma-Aldrich).  
Samples were allowed to slowly freeze at -80°C overnight and then transferred to 
liquid nitrogen for storage until needed.  Cells were rapidly thawed in a 37°C water bath, 
diluted to 10ml in RPNK media supplemented with 50U/ml benzonase (Novagen) (RPNK 
media: RPMI 1640 (Cellgro) supplemented with 10% FBS (Atlanta Biologicals), 2% 
Penicillin - Streptomycin (5000U/ml, 5000µg/ml respectively, GIBCO, Invitrogen) and 1% 
L-glutamine (29.2mg/ml, GIBCO)).  Cells were then counted using a hemocytometer and 
divided into separate fractions for flow cytometry or RNA processing. 
 
Peptide MHC class I tetramers reagents  
Commercial tetramers were acquired from Beckman Coulter: Human CMV 
pp65495-503 (NLVPMVATV)-A*0201, CMV pp65417-426 (TPRVTGGGAM)-B*0702, CMV 
pp65123-131 (IPSINVHHY)-B*3501, CMV IE188-96 (ELRRKMMYM)-B*0801, Influenza A 
Matrix-158-66 (GILGFVFTL)-A*02; EBV BMLF1259-267 (GLCTLVAML)-A*0201 ready to use. 
Biotinylated MHC-peptide monomers from the National Institute of Health (NIH) tetramer 
facility were obtained for the following: EBV BRLF1109-117 (YVLDHLIVV)-A*0201, EBV 
BRLF1147-155 (RVRAYTYSK)-A*03, EBV BZLF1190-197 (RAKFKQLL)-B*08; EBV 
EBNA3A325-333_ (FLRGRAYGL)-B*08, EBNA3A379-387  (RPPIFIRRL)-B*07, EBNA3A603-611 
(RLRAEAQVK)-A*03.  Prior to use, we added PE-, APC-streptavidin (Invitrogen) to the 
monomers at a 4:1 molar ratio for O/N in the dark at 4°C to generate fluorescent pMHCI 
tetrameric complexes.  All tetramers were stored in the dark at 4°C. 
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Flow cytometry analysis 
PBMCs from each subject were stained with antibodies (e-Bioscience, 
Biolegend, or Invitrogen) against CD3, CD4, CD8, CD38, CD45RA, HLA-DR, peptide-
MHCI tetramers (NIH tetramer facility or Beckman Coulter), washed, permeabilized, and 
then stained with an antibody to Granzyme B using the BD Cytofix/Cytoperm Kit per 
manufacturer’s instructions (BD Biosciences).  Samples were analyzed on a LSR II 
(Becton Dickinson) and all data was processed using the FlowJo Software from 
Treestar. 
 
Statistical Analysis 
All statistical analysis was performed using Prism software (Graphpad).  
Comparisons between groups were performed with either an unpaired two-tailed t-test , 
a paired two-tailed t-test (Fig. 5 and Fig. 8) or a one-way ANOVA with a p value less that 
0.05 as the cutoff for statistical significance. 
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CHAPTER 4 
 
Discussion/Conclusion 
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Discussion 
In contrast to the 18,000 articles published on “EBV”, there are approximately 
1500 articles in a Pubmed search for “ EBV infectious mononucleosis”.  Much of the 
EBV field has focused on immune impairment and EBV-related tumorigenesis due to the 
morbidity and mortality that can occur.  This is partly due to an early study that 
suggested that IM was associated with CD8 lymphocytosis and not viral load in the 
blood 130.  Furthermore, anti-viral medications have had limited to no efficacy in treating 
IM 154-158,160,222.  Therefore, the scientific field has, in general, accepted based on limited 
and circumstantial evidence that the viremia itself does not contribute to the 
immunopathologic symptoms observed during infectious mononucleosis 121.  
This is in contrast to the widely accepted notion in immunology that pathogen 
load is an important determinant of disease outcome.  To date, only one other study has 
examined disease severity and viral load 48.  Although this group did not measure cell-
mediated immune parameters, they did observe a strong association with disease 
severity and viremia 48.  Hence, the issue of what factors are associated with severe 
disease in response to primary EBV infection is still controversial.  Reconciling these 
studies is key to determining potential therapeutic targets for primary EBV infection and 
EBV-related sequelae. 
The work presented in this thesis provided insight into the mechanisms of 
protective immunity that may be important during primary EBV infection.  We began by 
using a prospective study model to understand the basic immune responses to a natural 
primary EBV infection in humans and to facilitate capture of asymptomatic 
seroconversion to primary infection.  Based on published data, we expected the 
incidence of infectious mononucleosis to be approximately 25% 121.  However, to our 
surprise, our data revealed that primary EBV infection results in clinical symptoms in 
90% of individuals.  When we compared clinical score and duration of illness in a 
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prospective study to that of a clinical study, we found approximately a 50% increase in 
both parameters.  Based on these data, we concluded that studies that recruit 
participants from health services result in a distorted view of primary EBV infection 
because they focus on the most severe arm of infectious mononucleosis subjects. 
Using this methodology, Chapter 2 describes the first prospective study, to our 
knowledge, that extensively analyzes acute primary EBV infection.  We began by 
defining the peaks of viral load in the blood and oral cavity, CD8 lymphocytosis and NK 
cell expansion.  Interestingly, the peak of the immune response occurred within the first 
two 2 weeks after symptom onset.  At the peak of response, a majority of the CD8 T 
cells displayed (and to a lesser extent CD4 T cells) an activation phenotype (CD38, DR, 
GrzmB).  The contraction and memory phase of the immune response was observed in 
some individuals to start as early as the third week after symptom onset.  Moreover, we 
could not detect virus in the blood or oral cavity in most individuals prior to onset of 
symptoms.  Since the estimated incubation period for development of primary infectious 
mononucleosis in response to EBV infection is between 32-49 days 178, the data support 
a model in which acute EBV infection results in a highly robust but delayed T cell 
response more similar to chronic viral infections like HIV and Hepatitis 183.  Therefore, 
although there is a long incubation period before the T cell response is visible, EBV is 
not unlike other chronic viral infections. 
The design of the prospective model then allowed us to address whether disease 
severity was associated with CD8 lymphocytosis and/or EBV viremia.  Here, we found 
that viremia, CD8 lymphocytosis and NK cell expansion all correlated with disease 
severity.  Viral infection can result in the activation of pathogen associated molecular 
patterns such as toll-like receptors (TLRs), and subsequent activation of the innate 
immune system.  Furthermore, viral antigens can engage T cell receptors and drive 
antigen specific proliferation of the adaptive immune system.  Therefore, if viremia is the 
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determinant of NK cell and CD8 T cell expansion, we expected to see a positive 
correlation.  An association between viremia, but not oral viral load, and both NK and 
CD8 T cell expansion corroborated this.  One advantage of a prospective study is that 
we have banked PBMCs from EBV-naïve stages of all our subjects.  Therefore, one 
potential experiment would be to compare, in vitro, the immune response of multiple 
individuals to varying amount of copies of EBV.  If we observed similar proliferation 
across multiple individuals that correlated with EBV copy number used as stimuli, then 
this would also support an important role for EBV.  
Next, we attempted to determine if any cytokines correlated with disease 
severity.  Interestingly only IL-6 correlated with disease severity.  IL-6 is a pleiotropic 
cytokine that plays an important role in immune regulation (innate and adaptive 
responses) and inflammation 223.  IL-6 is both a pro- and an anti- inflammatory molecule, 
which may be produced early by endothelial cells, and transignalling by IL-6 suppresses 
neutrophilic immune responses in part by inducing apoptosis	  224.  Furthermore, IL-6 in 
tissues also results in enhanced monocyte recruitment, and can skew T cell 
differentiation towards T-helper 2 and T-helper 17 224.  Therefore, it is possible that we 
observed a reduced disease severity because IL-6 is skewing the immune response 
away from a T-helper 1 (IFNγ) response.  
However, based on the mouse model of EBV, mouse gammaherpesvirus 68 
(MHV-68), we hypothesize that IL-6, per se, is not as important as viremia. Similar to 
humans, IL-6 is elevated during MHV-68 infection225, however, IL-6-/- mice infected with 
MHV-68, do not differ in viral load in the lymphoid tissues (spleen and lymph node), CD8 
T cell lymphocytosis or cytokine production from wild-type mice 226.  Yet, we cannot 
assume based on the mouse data, that IL-6 is negligible during acute EBV infection; 
therefore, more extensive analysis may be needed to determine the mechanism and role 
of IL-6 in development of IM in humans. 
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The data presented here does not refute the contribution of CD8 lymphocytosis 
to disease pathology, as we observed a strong correlation between CD8 lymphocytosis 
and both disease severity and duration of illness.  Instead, we highlighted the 
contribution of viral load in the blood to CD8 T cell (and NK cell) expansion. As stated 
earlier, one rationale for CD8 lymphocytosis is the recruitment and activation of 
bystander T cells from the pre-existing memory CD8 T cell repertoire. However, previous 
reports are at odds as to whether or not, all CD8 lymphocytosis is EBV-specific 186,227.  
Furthermore, multiple studies have observed bystander activation of pre-existing 
memory T cells.  
Thus, in Chapter 3, we defined the interactions between a robust immune 
response on the pre-existing memory CD8 T cell compartment in a chronic infection in 
humans.  For the first time, we showed bystander activation of Flu- and CMV-specific T 
cells during primary EBV infection.  While bystander pre-existing memory CD8 T cells in 
general did not expand, we did not perform exhaustive analysis to determine the specific 
contribution of pre-existing memory to the expanded CD8 T cell population for each 
individual.  Therefore, put together with the multiple chronic infections that each 
individual has been exposed to, heterologous immunity 135,180 may still be, in part, 
contributory to the dramatic CD8 T cell expansion observed during acute primary EBV 
infection.  
 
From Bench, To Bench, To Bedside 
In Chapter 2, we insinuated that the symptoms of IM may be ameliorated using 
antivirals. Although one study showed a partial effect with valacyclovir 58, other studies 
have not 154-158,160.  Given that certain antiviral drugs effectively reduced viral loads	  58, the 
lack of reduced clinical disease is presumably because IM is typically not diagnosed until 
a person seeks treatment due to persistent symptoms which results in delayed therapy 
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initiation relative to the onset of symptoms.  Furthermore, based on a study showing that 
continuous valacyclovir treatment results in reduced EBV infected B cells over time in 
healthy carriers 228, it would be interesting to determine the effectiveness of reducing IM 
symptoms and duration using extended antiviral regimen that avoid the viremia rebound 
detected after a 14-day valacyclovir schedule 58.  
Another potential way to reduce viremia or prevent IM would be to immunize EBV 
naïve individuals with an EBV vaccine 170.  Also known as EBV-induced membrane 
antigen, gp350 protein facilitates infection by binding to CD21 on B cells 12 and 
preliminary results of a gp350 subunit vaccine have been promising 124,125,127.  In general, 
gp350 vaccines have been immunogenic, eliciting anti-gp350 antibodies (including 
neutralizing antibodies) in most subjects 1 month after the final vaccination 124,125,127.  
Moreover, gp350-specific cell mediated responses have also been induced during 
vaccination as demonstrated by inhibition of the outgrowth of transformed B cells 125 and 
the incidence of infectious mononucleosis was reduced (efficacy= 78%) in a small cohort 
127.  However, in a transplant study to prevent lymphoproliferation in EBV naïve children, 
a three-cycle gp350 vaccine schedule did not reduce viral load 126 warranting the need 
for further development of gp350 vaccine protocols.  Furthermore, it is key to 
characterize oral and whole blood viral load, CD8 T cell, CD4 T cell, and NK cell 
responses, in addition to the humoral immunity elicited by gp350 immunization in healthy 
individuals for complete understanding of immunity to EBV. 
Strategically, if the aim is to modulate the CD8 T cell immune response during 
acute primary EBV infection, it is important to determine the impact of this chronic 
infection on the stability of pre-existing memory T cells.  In Chapter 3, we showed that 
primary EBV infection did not result in attrition of memory CD8 T cells specific for Flu 
and CMV.  However, we did not determine if attrition of naïve (both antigen specific and 
self-specific) CD8 T cells occur after IM.  If primary EBV infection results in depletion of 
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naïve precursor CD8 T cells, the potential impact on the ability to recruit adequate naïve 
CD8 T cells precursors during subsequent challenges to the immune system will be 
important to study and understand.  We could also determine if primary EBV infection 
resulted in attrition of virus-specific cells that do not undergo secondary challenge, such 
as in subjects vaccinated with the yellow fever vaccine.  Our group will most likely 
perform these experiments in the future. 
Overall, the data suggest that EBV viral load in the blood (i.e. viremia) is an 
important driving force for both innate (NK cell expansion, IL-6 production) and adaptive 
(CD8 expansion) immunopathologic responses that result in the development of 
infectious mononucleosis during primary infection.  Furthermore, the data would support 
a model in which an initial inadequate control of viremia (and not local (tonsillar) 
infection) propagates a massive but sub-optimal T cell response, which results in 
prolongation of infectious mononucleosis symptoms.  Hence, these results provide 
several insights into an acute cell-mediated response to a persistent chronic virus in 
humans. 
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